Psyence Group Invited as First Psychedelic Company to present at the 15th-Annual Global Wellness Summit – GlobeNewswire

TORONTO, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (Psyence or the Company), a life science biotechnology company with a focus on natural psychedelics in mental health and well-being, will break new ground as the first psychedelic company invited to speak at the 15th Annual Global Wellness Summit, a gathering of international leaders in the $4.5 trillion global wellness economy.1 Meeting in Boston November 30 to December 3, 2021, thesummit includes doctors, activists, and health care executives from research organizations that include Harvard, Massachusetts Institute of Technology (MIT), Cleveland Clinic and elsewhere.

Psyences Head of Corporate Social Responsibility, Mary-Elizabeth Gifford, will host an in-person keynote conversation with Rick Doblin, PhD, Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) on the future of Psychedelics and Healing.

A psychedelic researcher and activist, Doblin isrecognized for his work de-stigmatizing psychedelics through evidence-based scientific research. His organization,MAPS, is sponsoring Phase 3 clinical trials of MDMA-assisted therapy for PTSD.

Mary-Elizabeth Gifford, chair of the non-profit Global Wellness Institute's Psychedelics & Healing Initiative, leads Corporate Social Responsibility for the Psyence Group, where she works to democratize responsible psychedelic and nature-based solutions for mental health and wellness that also help heal and strengthen the wider community. The Keynote Conversation with Gifford and Doblin takes place December 1st, 2021, at 4:10pm EST. This event is in person and registration can be accessed virtually at https://www.globalwellnesssummit.com.

ABOUT PSYENCE GROUP: http://www.psyence.com

Psyence is a public life science biotechnology company listed on the Canadian Securities Exchange and (CSE: PSYG) and quoted on the OTCQB (OTCQB: PSYGF), with a focus on natural psychedelics. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.

Our name Psyence combines the wordspsychedelicandscienceto affirm our commitment to producing psychedelic medicines developed through evidence-based research.Informed by nature and guided by science, we built and operate one of the worlds first federally licensed commercial psilocybin mushroom cultivation and production facilities.

Our team brings international experience in both business and science and includes experts in mycology, neurology, palliative care, and drug development. We work to develop advanced natural psilocybin products for clinical research and development. We have entered into a long term joint venture to launch mushroom-based mental wellness focused nutraceutical products, the GOODMIND collection, to support improved focus, calm, and sleep.

Our key divisions, Psyence Production, Psyence Therapeutics, and Psyence Function, anchor an international collaboration, with operations in Canada, the United Kingdom, Jamaica, South Africa and a presence in the United States and Australia.

Contact Information:Lisa-Marie Iannitelli, Investor RelationsEmail:ir@psyence.com

Media Inquiries: media@psyence.comGeneral Information: info@psyence.com

1 https://globalwellnessinstitute.org/press-room/statistics-and-facts/; https://www.forbes.com/sites/forbesbusinessdevelopmentcouncil/2019/10/14/why-the-wellness-business-is-booming-and-how-to-succeed-in-the-industry/?sh=731f0b7c41aa

See more here:

Psyence Group Invited as First Psychedelic Company to present at the 15th-Annual Global Wellness Summit - GlobeNewswire

Psychedelics can change humanity for the better. Its time to unlock their power – The Guardian

I study psychedelics. The organization I work for the Multidisciplinary Association for Psychedelic Studies (MAPS) has been researching MDMA since 1992, seven years after the substance was prohibited. Our organization was founded in 1985.

One of a few treatments designated a breakthrough therapy by the FDA, MDMA-assisted therapy for post-traumatic stress disorder is an incredibly promising treatment for this devastating mental injury. Survivors of PTSD may struggle to stay connected in their work, families, and communities. They often live with symptoms like insomnia, hyper-vigilance and isolation; these commonly lead to substance use disorder, depression, chronic pain or heart problems. Yet most of the available treatments provide symptom relief for only about half of the people with the diagnosis, with even fewer people experiencing remission.

In May 2021, Nature Medicine published the results of the most advanced trial of psychedelic therapy to date. In our Phase 3 trial of MDMA-assisted therapy for PTSD, 88% of participants who received MDMA in conjunction with trauma-focused therapy experienced a clinically significant reduction in symptoms; 67% of participants no longer met criteria for a PTSD diagnosis. Many participants reported MDMA-assisted therapy helped them address the root cause of their trauma for the first time.

An exploratory study suggests a role for MDMA in couples therapy. MAPS has combined its MDMA-assisted therapy protocol with Cognitive Behavioral Conjoint Therapy (CBCT) for PTSD, in which both the person with PTSD and their partner are administered MDMA. Results demonstrated dramatic reductions in PTSD symptoms and partner accommodation, improving the quality of relationships for six couples.

Ketamine studies have shown promise for chronic suicidal tendencies, PTSD symptoms and depression. Legal ketamine clinics which pair therapy with the drug can play a key role in maximizing the benefits and reducing the risks of the psychedelic experience. Psilocybin-assisted therapy is a breakthrough therapy for depression. Ibogaine may be an effective treatment for opioid use disorder.

In fact, four separate systematic reviews have been published this year highlighting the potential of psychedelic-assisted therapies for those conditions and more: end of life care, brain injury, neurodegenerative disorders, mood disorders, smoking cessation and addiction or dependence. Dozens of studies make a compelling case for rapid expansion of research into psychedelic-assisted therapies for serious mental health conditions.

Evidence indicates that psychedelic use is associated with pro-social, personal growth benefits including increased nature relatedness, potentiating conflict resolution and sustaining compassion among first responders. Indigenous communities around the globe have used psychedelics in spiritual ceremony and healing for millennia.

Conversely, the well-documented devastation of the war on drugs has been responsible for untold trauma. But is the legalization and regulation of all substances reversing the course on the war on drugs too dangerous? Simply: No. Its more dangerous not to.

Decades of research and far more extensive use outside clinical settings demonstrate that the risks of drugs, for most people, are generally short-term and manageable through compassionate risk-reduction measures. For those who become dependent on drugs, treatment-on-demand is a more effective intervention than criminalization. In lieu of a legal, safe supply of substances, drug checking can identify adulterants like fentanyl. Peer support is so successful in transforming emotionally challenging experiences that Denvers first responders and police officers will soon be trained in the method as an alternative to criminalization or sedation.

Last year, Oregon became the first US state to decriminalize the possession of most drugs and to create a legal system for supervised psilocybin experiences. California, Vermont and Hawaii are actively considering new legal frameworks for psychedelics; Texas is directing state funding to research. In the face of an epidemic of veteran suicide, the US veterans administration is hosting small psychedelic-assisted therapy trials. Members of Congress from both sides of the aisle support federal funding. Lawmakers, regulators, funders, insurance providers and therapists who take a clear-eyed look at the research may be surprised to find their fears dissolving.

MAPS recognizes that the people who are most marginalized by society are often those who are most traumatized, have least access to a diagnosis and even less access to adequate treatment. MAPS is working with researchers around the world to facilitate studies of psychedelic-assisted therapy with refugees, transgender communities, first responders exhausted by Covid, people of color subjected to racial trauma and more. We envision a day when psychedelics will be more than a last-ditch treatment: they will be a catalyst for mass mental health.

View original post here:

Psychedelics can change humanity for the better. Its time to unlock their power - The Guardian

Weekly Roundup on the Cannabis Sector & Psychedelic Sector – Yahoo Finance

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector

Marijuana multistate operator Jushi to acquire Nevadas NuLeaf in a deal worth $62.5 million.

Village Farms buys Quebec cannabis producer for CA$46.7 million.

Schwazze acquires a Colorado marijuana store for $4 million and stock; and spends $29 million to acquire two more Colorado cannabis retailers.

WM Technology to acquire marijuana marketing platform Sprout.

Key Takeaways; Psychedelic Sector

According to marijuana research company BDSA, the global cannabis and psychedelic market will be worth more than $100 billion by 2026, growing at a compounded annual growth rate (CAGR) of over 15%. But those numbers could go even higher as more states pass legislation that permits marijuana and psychedelics for medical or recreational use.

Top Cannabis Stocks to Keep a Close Eye On

#1: Jushi Holdings

Jushi Holdings Inc. (OTCMKTS: JUSHF) is a vertically integrated cannabis company that engages in the cultivation, processing, retail, and distribution of medical and adult-use products. It focuses on building a portfolio of cannabis assets in various jurisdictions in Pennsylvania, Virginia, Ohio, Illinois, California, Nevada, and Massachusetts.

The Florida-based multistate marijuana operator announced a deal to acquire NuLeaf, a vertically integrated cannabis company in Nevada. The acquisition is worth up to $62.5 million and is expected to close in the first half of 2022, according to a Wednesday, November 17 news release.

The price tag features a $52.5 million upfront payment that includes: $15.75 million in cash, an unsecured promissory note for the same amount, and $21 million in Jushi subordinate voting shares. Another $10 million in an identical percentage combination of cash, a promissory note, and shares will be issued upon the occurrence or non-occurrence of an upcoming NuLeaf dispensary on the Las Vegas strip receiving regulatory approvals to open for business.

Story continues

The NuLeaf acquisition comes on the heels of Jushis deal to buy Las Vegas retailer The Apothecarium and its acquisition of Nevada cannabis cultivator, processor, and distributor Franklin Bioscience NV.

#2: Village Farms

Village Farms International, Inc. (NASDAQ: VFF), together with its subsidiaries, produces, markets, and distributes greenhouse-grown tomatoes, bell peppers, and cucumbers in North America. It operates through three segments: Produce Business, Energy Business, and Cannabis and Hemp Business.

On September 15, 2021, Village Farms bought a majority stake in Quebec-based licensed cannabis producer and distributor Rose LifeScience, fulfilling the Florida-headquartered companys pledge to gain a foothold in Canadas second-biggest marijuana market by population.

Village Farms, the parent company of British Columbia cannabis producer Pure Sunfarms, bought 70% ownership of the privately held business for up to 46.7 million Canadian dollars ($37 million), consisting of CA$19.9 million in cash and CA$26.8 million in shares.

In a September interview, Village Farms CEO Michael DeGiglio said the company was focused on entering the promising Quebec market. In a note to investors, Doug Cooper, a Toronto-based analyst for Beacon Securities, said the acquisition likely would enable the company to sell Pure Sunfarms products in Quebec.

With Quebec as the final piece of the Canadian puzzle, Pure Sunfarms will now be selling to more than 90% of the Canadian population, the analyst wrote, adding that likely secures the market the company needs to bring the second half of its 1.1 million-square-foot BC facility into production.

In Quebec, Rose distributes its own brand of cannabis products. It is also the distribution entity for cannabis producers Entourage Health, Sundial, Tilray, The Flowr Corp, and 10 micro and craft growers.

The deal includes Roses 55,000-square-foot cultivation and processing facility in Quebec. Under the agreement terms, Rose CEO Davide Zaffino and Chief Operations Officer Brian Stevenson will remain in their current roles after the acquisition. They will also retain a 30% interest in the company they co-founded.

Village said the deal gives it a pathway to acquire the remainder of Rose if certain milestones are met before March 31, 2025. Shares of Village Farms International are traded as VFF on the Nasdaq and Toronto Stock Exchange, respectively.

#3: Schwazze

Schwazze (OTCQX: SHWZ) is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale. The company is building the premier vertically integrated cannabis company in Colorado and plans to take its operating system to other states to develop a differentiated leadership position. Medicine Man Technologies, Inc. was Schwazzes former operating trade name. And the corporate entity continues to be named Medicine Man Technologies, Inc.

On November 16, 2021, the Colorado-based retail chain said it acquired the cannabis shop Smokin Gun Apothecary in the Denver suburb of Glendale for $4 million and 100,000 shares of stock.

The vertically integrated Schwazze has been on an acquisition spree, having gobbled up indoor cultivator Brow 2 in August for $6.7 million, Southern Colorado Growers in July for $11.3 million, and retail chain competitor Star Buds in March for $72.3 million. The addition of Smokin Gun brings its retail store footprint to 20.

The transaction, expected to close in the fourth quarter of 2021, includes the retail store and Smoking Gun Land Co.

On Wednesday, November 17, 2021, the quickly growing Colorado retail chain said it had acquired two more cannabis shops in its home state, bringing the companys store count to 22. According to a news release issued Tuesday, Schwazze agreed to pay $29 million for MCG, which does business as Emerald Fields and has shops in Glendale, a Denver suburb, and Manitou Springs.

The deal is expected to close within 75 days and will be paid 60% in cash and 40% in Schwazze stock. The deal was the second acquisition in a week for Schwazze, which has been on an acquisition tear through much of 2021.

#4: WM Technology

WM Technology, Inc. (NASDAQ: MAPS) provides SaaS subscription offerings to retailers and brands in the United States and Canadian cannabis markets.

The Irvine, California-based WM Technology, a cannabis special purpose acquisition company (SPAC), said it acquired Sprout, a cloud-based customer relationship management and marketing platform for the marijuana space. However, the terms of the deal were not disclosed.

WM Technology is the parent company of Weedmaps, a digital marijuana retail directory that offers such features as menus and online ordering. The company went public in June after merging with SPAC Silver Spike Acquisition Corp.

According to Chris Beals, CEO and chair of WM Technology, the acquisition is expected to help clients target, reach, acquire, and retain customers at scale. Sprout is used by cannabis dispensaries and brands in the U.S., Canada, and Puerto Rico.

With the addition of Sprout, we are one step closer to realizing this vision of providing an all-in-one seamless and integrated solution to run, manage and grow ones cannabis business, Beals said in the release.

Top Psychedelic Stocks to Keep a Close Eye On

#1: Awakn

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) is a biotechnology company that engages in researching, developing, and delivering psychedelic therapeutics to treat addiction other mental health conditions in the United Kingdom and Europe. The company is headquartered in Vancouver, Canada.

This week Awakn announced that it had signed a Memorandum of Understanding (MOU) with Devon Partnership NHS Trust (a provider of mental health services to <1 million people living in Devon, south-West England) and the University of Exeter.

The proposed partnership intends to enhance the evidence base for ketamine-assisted psychotherapy as an alternative treatment for Alcohol Use Disorder and treatment-resistant depression within the NHS. At present, Brits looking to access these therapies must do so by paying out-of-pocket: a practice that is much rarer in the UK vs. the US, for example.

#2: MindMed

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness.

The Nasdaq-listed company announced that it had begun recruitment for a randomized placebo-controlled study evaluating the effects of daytime and evening administration of repeated low doses of LSD.

MindMed will measure the effects of LSD microdoses on neuroplasticity markers such as BDNF plasma levels, as well as measures of sleep, mood, cognitive performance, and more. Dr. Kim Kuypers at Maastricht University will lead the study.

The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exclusive.


Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Yahoo Finance

New study finds ‘microdosing’ psychedelics can be effective in treating anxiety, depression | TheHill – The Hill

A new study is adding to the growing body of research suggesting the use of certain hallucinogens can help treat people battling mental health disorders.

A study recently published in Nature: Scientific Reports found the use of small doses of psychedelics such as psilocybin, the active ingredient found in magic mushrooms, or LSD resulted in a reduction of anxiety and depression symptoms among participants.

The international study led by the University of British Columbia Okanagan (UBCO) included more than 8,500 people from 75 countries who used an anonymous self-reporting system. About half of the participants were "microdosing," or consuming very low quantities of psychedelics, while half were not.

In comparing microdosers and non-microdosers, there was a clear association between microdosing and fewer symptoms of depression, anxiety and stresswhich is important given the high prevalence of these conditions and the substantial suffering they cause, Joseph Rootman, UBCO doctoral student and the studys lead author, said in a statement.

America is changing faster than ever! Add Changing America to your Facebook or Twitter feed to stay on top of the news.

Researchers also said the study is the first to examine the practice of combining small doses of psychedelics with other substances such as niacin, lions mane mushrooms and cacao.

Over the past several years, numerous studies have shown small doses of psychedelics psilocybin specifically have resulted in improvements in the levels of depression among participants.

A 2016 study looked at whether the drug could help with symptoms of cancer-related depression and anxiety. A group of cancer patients were given a single dose of synthetic psilocybin and reported their anxiety and depression symptoms eased. A 2020 follow-up study found many participants were still feeling the positive effects of the treatment years later.








New study finds 'microdosing' psychedelics can be effective in treating anxiety, depression | TheHill - The Hill

Psychedelics stocks were all the rage a year ago. What happened? – The Globe and Mail

A blister pack of Ketamine lozenges at the psychedelic therapy clinic in Toronto on Aug. 28, 2020.COLE BURSTON/AFP/Getty Images

It was barely a year ago that psychedelics stocks were all the rage among investors, drawn to grandiose promises by companies that drugs such as LSD and magic mushrooms could produce game-changing treatments for anxiety, depression and addiction.

But that investor euphoria peaked in March, 2021. Since then, despite a handful of promising clinical trials, and a growing number of U.S. states introducing bills to decriminalize psychedelic substances, shares of many psychedelics companies have performed poorly, sharply declining in value over the past six months.

This disconnect, analysts say, can be blamed primarily on retail investors who seemed to associate psychedelics companies with sales-driven cannabis producers, rather than thinking of them as biotech firms that will take years to begin generating revenue.

While the performance of Canadian cannabis companies hinged on consumer demand for a product that became legal for recreational use in October, 2018, most psychedelics companies are involved in early-stage scientific research on how specific chemical compounds that make up drugs such as ketamine, LSD and MDMA could potentially be used in treating mental-health conditions.

For the biggest companies in the space, their business model is fundamentally a biotech one, explained Michael Freeman, a health care sector analyst with Raymond James Financial. These are companies that will spend years running randomized, controlled, clinical trials of psychedelic molecules to determine their efficacy. It is a very different value proposition than cannabis.

Field Trip Health raises largest financing in Canada for a psychedelics company

The shiny new object: Despite being illegal, retail investor rush to psychedelics resembles euphoria around cannabis

The lacklustre performance of psychedelics stocks is clearly evident in how the worlds first psychedelics exchange-traded fund a basket of stocks comprising more than 20 companies in the sector has fared. Since its launch in January, the Horizons Psychedelics Stock Index ETF has plunged by 36 per cent.

Although the index is rebalanced quarterly, it was initially weighted heavily in favour of some of the most well-known psychedelics companies, such as MindMed Inc., and Compass Pathways Inc. The share prices of both companies have dipped by more than 40 per cent since the height of investor excitement in early 2021.

People saw it as a get-rich-quick industry, but as the months went by investors realized this is nothing like cannabis. These are heavily regulated substances that have to go through many clinical trials, so you would want to stay with the company to reap the benefits, said Tania Gonsalves, an analyst with Toronto-based Canaccord Genuity Inc.

MindMed was heavily promoted and championed by Shark Tanks Kevin OLeary, who famously told Business Insider in November, 2020, that investors burned by bad bets on cannabis startups should not be afraid to gamble on psychedelics.

The New York-based company specializes in developing molecules of LSD, MDMA and psilocybin the hallucinogenic chemical in certain mushrooms for the treatment of depression.

It was the first psychedelics company to go public (in March, 2020), on Torontos NEO Exchange, and now trades on Nasdaq as well.

But while MindMed shares have gained a whopping 425 per cent since the company made its public debut at 40 cents, they have declined by almost 50 per cent since the psychedelics market peaked in February, around the time Horizons launched its psychedelics ETF.

Unfortunately we launched the ETF six months too late, admitted Steve Hawkins, chief executive officer of Toronto-based Horizons ETFs Management Inc. A lot of the companies in our portfolio are up triple digits since they went public. But on a six-month basis, many of them are down.

Mr. Hawkins told The Globe and Mail that Horizons has had to consistently rebalance its psychedelics portfolio because the sector is volatile. These companies are all over the place. All it takes is one piece of news whether it be fact or fiction to create significant volatility with the underlying portfolio.

On Nov. 9, Britain-based Compass Pathways announced much-anticipated results of a 233-patient study of the use of psilocybin in treatment-resistant depression, finding that the patient group receiving the highest dose of COMP360 (a molecular derivative of psilocybin) exhibited significant reduction in depression symptoms compared with those who received a lower dose.

Analysts covering the company ranked the result as neutral to positive. Yet Compass shares sank roughly 20 per cent after the news, as many investors seemed to determine it was the right time to exit the stock.

Mr. Freeman said the reaction is typical in the psychedelics space, which is dominated by retail investors.

Proper biotech investors make decisions based on when a company does data readouts, meaning, when [companies] have tangible results from a clinical trial that gets them to a new phase to proceed in research, Mr. Freeman explained. So biotech stocks generally move either up or down depending on which stage in the research process investors want to take their profit.

Andrew Partheniou of Stifel Financial Inc., another analyst who covers psychedelics companies, said he was surprised at how the market reacted to Compasss clinical trial results, which he deemed to be positive. I think for retail investors, it might have brought up questions on how well Compass could actually scale its therapies and what its real addressable market might be like.

Raj Lala, an investment manager and CEO of Evolve ETFs, a competitor to Horizons, said he chose not to launch a psychedelics ETF because he could not see the long-term growth potential of psychedelics companies. It feels like a fad, Mr. Lala added, drawing a comparison to the cannabis sector. Evolve had launched two cannabis ETFs, but terminated them less than two years later, after they lost more than 50 per cent of their value. We did not have a good experience in that space, he admitted.

But Mr. Hawkins of Horizons is in psychedelics for the long haul. This is early stage biotech investing, there will be hits and misses. Were going through a lull period right now, but Im hoping investors will understand there is significant long-term potential in these drugs.

Your time is valuable. Have the Top Business Headlines newsletter conveniently delivered to your inbox in the morning or evening. Sign up today.

Read more from the original source:

Psychedelics stocks were all the rage a year ago. What happened? - The Globe and Mail

I have ADHD and was scared of psychedelics. Then I found myself eating magic truffles … – The Guardian

If you had asked me pre-pandemic if I would ever touch psychedelics, I would have said absolutely not. The speed of my brain is literally my only skill. As a standup comedian and podcaster, I can walk out on stage with absolutely nothing in my head and riff with an audience for an hour if I need to which I know seems like a superpower to others while ordinary powers, such as the ability to do my laundry every week, elude me.

I was recently diagnosed with ADHD first in the green room by other comedians, then by a doctor. It seems that a lot of us comics have it. I guess its a job you can do if you are not neurotypical, because you see the world from an unusual angle and there is very little admin. I often see comics on Facebook posting: Ive just got Peckham in my diary for tonight; am I meant to be doing a gig for anyone there?

I am sure there are many people with ADHD who have trained themselves to be great in office environments, but I suspect its too late for me, so I really need to hold on to that talk-fast-and-mind-map skill. That is why at music festivals I always said no to anything that might change my brain chemistry. I had resigned myself to the fact that I would never see the face of God in a cloud, or myself as a baby cat on the ocean floor.

So, on one level, I was genuinely surprised to find myself consuming a cup of magic truffles at an entirely legal therapeutic retreat in Amsterdam. (These are a lot like magic mushrooms, but grow beneath the ground, rather than above.) At the same time, somehow it felt inevitable. The safe, repetitive domesticity of lockdown had made me face my demons and seek therapy, but it had also made me hungry for sensation and risk.

A friend had phoned me and told me that she had taken a trip to the desert and done ayahuasca. She said it had healed so many of her traumatised wounds with visionary reconciliations and not slowed down her speedy, creative brain at all. She said I should do it but I had to wait till I got the call. I said: Babe, you are literally calling me now this is the call. Her thinking was that it couldnt be a phone call it had to be more spiritual than that. I started looking for signs. They are there if you Google retreats in Amsterdam. You can get the Eurostar there now, you know.

But ayahuasca wasnt on the cards for me. Lars, the shaman at the retreat that I settled for, said it was probably better to do truffles if youve have never done any psychedelics at all. He handed me a little bowl of truffles and told me to eat them all, then to lie down in the next room as soon as I needed to. I assumed I would be in a field staring at trees, but this is a therapeutic dose under supervision. You cant walk or talk.

Soon I was in a room alone under a duvet cover covered in dancing flowers. The wardrobe in the corner was animated like something out of Beauty and the Beast. I thought I would close my eyes to get away from it for a minute, but that made the visions much more intense. I saw the whole of the 60s in an hour. I understood every album cover I had ever seen. Not long after, I was in the womb and then the afterlife.

It didnt feel scary at all it was like I had gone back to the ground and become part of the energy of the world. Still alive, but rested, without the constant demands of email. I saw people in my life in new and revelatory ways, as well as the first act of feminism in the rebellion of the Garden of Eden. When Lars checked on me, I said: I dont know if youre real or not, but this is how religions are started, isnt it? He said: Yes.

I came out of it after four hours. My brain was as fast as ever, but at some kind of new and unusual peace. My therapist in New York reassures me that much research is going on around the world into the benefits of these natural substances for trauma sufferers.

Now, I have a gig in Peckham tonight. Does anyone know where it is?

Deborah Frances-White is a comedian, writer and the host of the podcast The Guilty Feminist. Arwa Mahdawi is away

Read the original post:

I have ADHD and was scared of psychedelics. Then I found myself eating magic truffles ... - The Guardian

Entheon Biomedical: Data and DMT among the keys to creating safe and effective treatments for patients battling addiction – Proactive Investors USA…

Entheon believes that it can provide better outcomes for people who have not been helped by previous types of addiction treatment

Entheon Biomedical Corp (CSE:ENBI, OTCQB:ENTBF) CEO Timothy Ko speaks passionately about his company and its objectives within the burgeoning psychedelics industry, not only because he heads one of the most dynamic teams in the space, but also because he credits psychedelics with saving his life.

Following a childhood of challenges that continued into his adult years, Ko ultimately found peace of mind after psychedelic intervention enabled him to look at life differently than he had been, repair important relationships and, as he puts it, learn to love again.

Kos experience defined what is now a life mission for him. This shined through in an eloquent and authoritative discussion with Canadian Securities Exchange Magazine in mid-September.

It would be difficult to come out of a conversation with Ko not believing that there is something to psychedelic treatments for those working to overcome mental illness. Its no longer about masking or dulling symptoms, but rather probing the drivers of problematic behaviour and replacing closely held, harm-inducing beliefs with new, healthier ones.

The specifics are best conveyed in Kos own words.

Proactive: Entheon is researching and developing products to help treat addiction. There are already products on the market that are used for this purpose. What are you trying to achieve with your treatments that existing alternatives do not?

Timothy Ko: I think before I answer that directly, we first have to look at the treatment landscape for addiction as it currently stands. When we assess treatment options available for various addictions be it tobacco, alcohol, or things like opiates we see a rather bleak landscape where many of the treatments, though widely available, are not particularly efficacious.

And looking at the population, it is estimated that, globally, over 2% of the population struggles with an alcohol or illicit drug addiction. In spite of the options currently available for addiction recovery we still see hundreds of thousands, if not millions, of people die every year as a result of tobacco, alcohol and opioid use disorder. The reality is that many people are rendered treatment-resistant over the course of multiple failed attempts to address their condition.

Entheon believes that we can provide better outcomes for people who have not been helped by previous types of treatment. In our estimation, the treatment-resistant form of addiction is more common than generally thought, and Entheon treatments are designed for people for whom other forms of treatment have failed.

Entheon focuses on a fast-acting hallucinogenic known widely as DMT. Does DMT have advantages over other psychedelics for addiction treatment?

Its important to demystify what psychedelics do. A really important observation of ours with DMT is that there is a feature that is present in other psychedelic molecules called entropy. Psilocybin, LSD and DMT can induce a state of heightened entropy, or randomness.

That might sound like a bad thing, but when you look at people with pathological conditions, there is often a degree of tunnel vision. These pathologies make it such that a severely depressed person, or an addicted person, is unable to look outside their normal frame of reference. Their reactions to stimulus or experiences are pre-determined, so you have this immobile state where they cannot envision a life outside of the one they have already experienced.

What DMT and other psychedelics do is to promote a state of hyper-connectedness. They allow individuals undergoing psychedelic treatment to enter a highly neuroplastic state that enables them to have entirely new experiences. In combination with therapy, they are able to experience old traumas, belief systems and memories, and rather than go to their pre-defined pathological reaction set, they are able to have perceptions that reshape their experience in a more positive way.

Where DMT is different is that it is very well metabolized by the body, which means the experience is short. Psilocybin is a bit of an unwieldy type of molecule to work with, as it is very powerful and the length of engagement is six to eight hours or longer. That window of engagement is commercially difficult to manage. And because these are such powerful experiences and the individual is often dealing with inherently difficult subject matter, the risk of an overwhelming experience is amplified.

With DMT, we can still facilitate powerful transformational experiences, but you have the benefit of being able to limit them to 30, 60 or 90 minutes. If we need to, we can stop the experience altogether and that person can return to a functional baseline in 10 to 15 minutes. If a person is having a difficult time with psilocybin, however, they are on that rocket ship for as long as the rocket has fuel.

In a recent news release, you discussed treatment algorithms through the Entheon IQ program. What is a treatment algorithm exactly, and what work is required to make the technology widely available?

The way Entheon sees the industry evolving is that there is a broad array of psychiatric conditions, as well as a broad spectrum of individuals appropriate for psychedelic use.

Not everyone will respond the same to different drugs. Different phenotypes will respond differently to different therapies.

What we are doing with Entheon IQ is taking a data-focused approach to look at what individual factors make different drugs and different treatment types appropriate for different individuals. We have acquired a company that has a genetic test that looks at a variety of mental health risk factors based on genetics, as well as a function of metabolic factors that dictate whether a person is more or less likely to have a strong or weak response to drugs. We believe genetics is a very strong component of ensuring that appropriate treatments are prescribed to the right people.

We are also on the verge of launching a study with a partner in Texas looking at different biomarkers associated with the ketamine experience, and were also looking at biomarkers associated with DMT.

Without generalizing too much, Entheon IQ and Entheon DNA are working to create biomarkers to help predict and direct appropriate treatments for individuals across a broad spectrum of psychedelic molecules and psychiatric disorders.

Talk to us about your business model. At what point does monetization become a reality, and how do you scale the business?

I think thats a question that the entirety of the psychedelic drug industry is looking at. The reality is that, as promising as the research is, in the interest of patient safety these development processes are bound to regulatory processes of governing bodies where we seek to commercialize.

We will need to make it through various stages of clinical validation, then have conversations with regulators and ensure our research is done in such a way that the data is irrefutable and highly understandable to the authorities that ensure these products are safe and effective.

The development timeline as it pertains to this approval process is five to 10 years, and we believe that we can have a timeline on the lower end of that range.

But in an earlier time frame, we think the development of tools to service the ketamine space should commercialize sooner.

You have a strong and growing advisory board of accomplished professionals in the addiction treatment space. Tell us how you choose new members for your team.

Our advisory board is among the best in the industry. It is populated by some of the most prominent and well-researched members in the psychedelic research space.

The psychedelic industry is under the general umbrella of science, yet it is highly specialized and the pioneers are limited to a very core group. When we started Entheon, we wanted to make sure we worked with minds that understood the unique properties of psychedelics better than other scientists.

Unlike other medicines that work in respect to brain chemistry, psychedelics take into account poorly understood features of the human psyche that are only now beginning to be characterized. We really wanted to select advisors with the most comprehensive understanding of the features of psychedelic medicine.

Lets close with a look at the industry in general. Do you come across misconceptions in the broader audience that you feel need to be cleared up?

The stigma associated with psychedelics often unfairly highlights radicalism or esoteric belief systems. There was a comprehensive anti-drug policy in the 1960s and 1970s that sought to vilify psychedelic drugs as potentially catastrophic to society and having no therapeutic value.

Rather than us having to dispel these myths, I think the research is truly bearing out a rebuttal to the notion that there is no therapeutic value to psychedelics. With each passing month, we see more research that shows huge transformational capacity to help people with end-of-life anxiety, nicotine addiction, as well as major depressive disorders.

We exist within a very interesting moment where on a purely scientific basis, not only are these substances not addictive, harmful or detrimental, but they may actually be the molecules with the therapeutic potential to disrupt a system that has seen very little innovation in the past few decades.

Contact Peter at peter@proactiveinvestors.com

Read more from the original source:

Entheon Biomedical: Data and DMT among the keys to creating safe and effective treatments for patients battling addiction - Proactive Investors USA...

The Reason I Was Wrong on Pot Stocks Is Why Im Right About This – Investorplace.com

Once upon a time, we were bullish on cannabis stocks.

We saw the statistics that young folks like to smoke/eat/ingest marijuana as much as they like to drink. We saw the political dominoes falling, one-by-one, with country after country legalizing pot. We connected the dots, and believed that we were entering a new world where young folks would buy a lot of legal marijuana over the next few years.

In fact, we believed this trend was going to create a $50+ BILLION global cannabis industry, and that out of that industry would emerge the marijuana-equivalent of Constellation Brands (NYSE:STZ), Molson Coors (NYSE:TAP), and Anheuser-Busch (NYSE:BUD) all alcoholic beverage giants worth a combined $150 billion.

But that time has passed. Now, were no longer bullish on cannabis stocks. In fact, instead of buying cannabis stocks, we think you should eliminate all exposure to the marijuana industry right now.

Source: TradingView


Because, while cannabis consumption trends remain strong and the legal backdrop continues to grow more supportive, the overwhelming majority of data today suggests that marijuana companies arent ever going to make huge profits.

You see, our initial bull thesis didnt just hinge on the cannabis industry getting really big (it will), but it also hinged on the idea that companies like Canopy Growth (NYSE:CGC) were going to be able to build big consumer brands in the cannabis industry and competitively monetize those brands at strong profit margins.

But recent trends imply that wont happen.

All of these cannabis giants just reported earnings. And while they all broadly reported healthy topline results, most of them also reported widening losses despite bigger revenues. The implication? Theyre spending to grow, and theyre earning negative ROI on that spend.

Why is this the case? Because the cannabis industry is entirely commoditized.

As it turns out, pot is pot. Sure, theres a difference in quality and strain. But your average consumer cannot tell that difference, and even if they can, most dont care. Those who can tell the difference and care represent a small segment of the population, and they already often have loyalty to a home-grown brand or their dealer down the street. They dont have loyalty to a Canopy Growth or Aurora Cannabis brand.

In the absence of meaningful product differentiation and brand loyalty, these cannabis companies are having to rely on price and distribution to drive competitive advantages.

Thats a losing ball game because you get into price wars where everyone loses, and spending on distribution only works until your competitor also scores the same distribution deals, in which case everything reverts to a lose-lose price war.

And that, in a nutshell, is why were bearish on cannabis stocks.

We were hopeful these companies were going to be able to turn supercharged demand for legal pot into huge revenues and profits. But, as each quarter passes and these companies lose more and more money, it has become clear that they wont.

Marijuana companies will forever struggle to make profits, and therefore, cannabis stocks will forever struggle to make you money.

Interestingly enough, though, our bearishness on cannabis stocks has made us doubly bullish on psychedelics stocks.

I know. Everyone likes to think of psychedelic stocks the companies making new, psychedelic-inspired treatments for mental health disorders as the second coming of cannabis stocks. But that couldnt be more false.

In reality, early-stage psychedelic companies like us recognized the shortcomings of their cannabis peers, and have done everything to make sure they dont fall into the same money-losing hole as cannabis companies.

Primarily, theyve developed competitive moats.

Whereas the cannabis industry is centered around making recreational pot accessible to everyone which opens the door up to commoditization the psychedelics industry is about making specialized medicines accessible to a small segment of the population.

These medicines have to be developed, and the science behind them is quite rigorous, meaning development is a huge barrier-to-entry. On top of that, they have to go through rigorous FDA trials another huge barrier-to-entry. They have to pass those trials another huge barrier-to-entry. And they have to win mass doctor approval yet another huge barrier-to-entry.

In other words, while the cannabis industry has essentially no barriers to entry, the psychedelics industry is comprised of nothing but barriers to entry.

Beyond that, psychedelics-inspired treatment isnt just about the medication. Its about the delivery of the medication. During treatment, patients need to be in controlled environments. They need to feel comfortable when taking the medication. They need to be safe. When not on the medication, they require therapy and counseling to optimize the medications effectiveness.

Its a whole process.

And guess what psychedelic companies are doing? Theyre trying to patent their whole process, meaning that at scale, psychedelic companies will have competitive moats not just around their medications, but around the delivery of those medications, too.

Folks the Shroom Boom is nothing like the Pot Boom. The latter is the archetype of commoditization. The former is the quintessence of building competitive advantages.

Which is why pot stocks are a horrible investment, but psychedelic stocks are a fantastic investment.

So, if you have any pot stocks in your portfolio, drop em. Forget about em. And take that money and go all-in with psychedelic stocks.

But, alas, heres the million-dollar question: What are the best psychedelic stocks to buy today?

To answer that, lets turn to our flagship investment research advisory, Innovation Investor.

In Innovation Investor, weve been following the psychedelics industry for a while now. Weve been through all the clinical trial results. Weve dug through all the companies in the industry. Weve talked to insiders and experts.

And, though it all, weve arrived at the conclusion that there is one shroom stock that everyone should buy right now before it soars to the moon.

To get the name, ticker symbol, and key business details of that tiny company and to access dozens of other hypergrowth tech stock picks right now click here.

On the date of publication, Luke Lango did not have (either directly or indirectly) any positions in the securities mentioned in this article.

Go here to read the rest:

The Reason I Was Wrong on Pot Stocks Is Why Im Right About This - Investorplace.com

Should psychedelics be decriminalized in California? The debate over current legislation is intensifying – CBS News 8

The state of Oregon has already decriminalized certain psychedelics, along with the cities of Seattle, Denver, Washington DC, Santa Cruz and Oakland.

SAN DIEGO COUNTY, Calif. Following three deployments to Afghanistan as a U.S. Army Ranger, veteran Jesse Gould returned to civilian life a changed man, dealing with intense bouts of anxiety and depression.

He was ultimately diagnosed with PTSD.

"There was nothing I could point to that made me happy, so I knew something had to change," Gould said. "Otherwise, I feared the worst at that point."

After some initial hesitation, and doing a lot of research, he decided to try a psycho-active plant-based treatment called ayahuasca.

"I just decided to take that leap of faith," he told News 8.

He traveled to Peru for a week-long retreat where, over the course of multiple indigenous ceremonies, he took ayahuasca in a closely-monitored environment.

"For me, there were very tangible benefits," Gould said.

Some studies show ayahuasca, whose active ingredient is the hallucinogenic drug DMT, can create feelings of euphoria, helping to treat anxiety and depression.

Gould said the treatment has helped him to deal more effectively with the trauma he had suffered.

"By the end of it, it was extremely apparent that it was completely different from what I had been told - the 'evil' that drugs are," Gould added.

Gould has now formed a nonprofit called Heroic Hearts Project, connecting veterans struggling with mental health issues to psychedelic therapy options.

He's also a vocal supporter of California Senate Bill 519 (SB519), statewide legislation that aims to decriminalize the possession and use of psychedelics like psilocybin mushrooms, LSD, DMT, mescaline, and MDMA.

Already, the state of Oregon has decriminalized certain psychedelics, along with the cities of Seattle, Denver, Washington DC, and here in California, Santa Cruz and Oakland.

"These drugs are saving people's lives," said State Senator Scott Wiener, who drafted this bill last year, and plans to re-introduce it in the upcoming legislative session.

"We have failed," Wiener told News 8. "The war on drugs has been an abysmal failure, so let's take a different approach and acknowledge that drug use is a health issue and not a criminal issue."

However, SB519 is facing intense opposition from a growing chorus of critics, from law enforcement to religious groups to anti-drug abuse nonprofits such as CASA, or Community Action Service Advocacy, based in San Diego.

"This isn't about stopping putting people in jail for using psilocybin, which really doesn't occur," said Dana Stevens, CASA's executive director. "It's really about just normalizing another whole layer of drug culture, and that's troubling because we see what happens to kids."

Senator Wiener counters that this legislation is specifically for those 21 and older.

"I don't see any protections," Stevens responded. "Just saying that it's for people 21 and over doesn't do it."

"Teenagers are using psychedelics now," Wiener said. "This isn't going to increase it or decrease it. It just means we are not going to be arresting people and throwing them in prison for possessing and using."

Jason Baker, a public health advocate for CASA, does not agree.

"We do not know the long-term repercussions of what we're doing here," Baker told News 8.

"My concern is that these drugs get into the hands of people that are already struggling with mental health issues and we just amplify the problem that we already have," he said.

Dr. Carl Hart, a neuroscientist at Columbia University who specializes in substance abuse and addiction, said that current research shows certain psychedelics, like MDMA, have shown promise in addressing mental health conditions.

"They can be hugely beneficial," Dr. Hart told News 8. "The scientific literature has shown this over and over. Study after study has shown that the drug decreases symptoms associated with post-traumatic stress disorder."

Another recent study indicates that psilocybin, taken for major depressive disorder, showed significant results after four weeks.

However, Stevens believes these drugs should first be approved by the FDA, not the state legislature, before being used as treatment.

"Take it through the proper scientific rigors of how we create medicine in America," Stevens said. "We have a system, and we've seen that system work."

Jesse Gould, though, said he may not be alive had he not found a treatment that worked for him.

"I know that if I kept rolling the dice that it eventually wouldn't go in my favor," he added. "So I am fortunate that I did find this when I did because everybody's luck runs out."

This legislation has already been passed by the State Senate and could be voted on by the Assembly in the spring or summer of next year.

See the rest here:

Should psychedelics be decriminalized in California? The debate over current legislation is intensifying - CBS News 8

Psilocybin patent highlights the swirling battle over psychedelics IP – STAT – STAT

One of the leading companies racing to develop psychedelics as legal medicines was granted a patent last week for a formulation of psilocybin the hallucinogenic compound found in magic mushrooms a decision that highlights the increasingly intense battle around intellectual property for potential medicines in this rapidly growing sector.

This is Compass Pathways fourth U.S. patent, but its first for a form of psilocybin the company isnt using in its clinical trials on treatment-resistant depression. The patent works to expand their intellectual property kingdom, said Mason Marks, senior fellow and project lead on the Project on Psychedelics Law and Regulation at Harvard Law School: Like a landlord would want to expand and buy more properties, theyre trying to lock up as much IP as they can to solidify their position in the market.

The patent, which covers a form of synthetic psilocybin known as Form A hydrate and methods of producing it, is useful to Compass as a way to restrict competitors who may be working with a different form of psilocybin. If another company creates psilocybin using that particular structure, then Compass will now have grounds to block them.


I have no doubts the reasons behind this are to protect a competitive position around psilocybin, said Graham Pechenik, patent attorney and founder of Calyx Law. The latest patent decision is likely to be challenged by those who believe that Form A hydrate is not new, and so cannot be patented.

Compass defended its decision to seek a patent for its formulation. As always were expecting challenges, said Compasss co-founder and president Lars Christian Wilde. We believe what weve found is novel and inventive. Were confident in our IP strategy.


Research and investment in psychedelics has accelerated in recent years. The U.S. Food and Drug Administration has granted breakthrough therapy designation to psilocybin and MDMA (also known as molly or ecstasy), for treatment of depression and PTSD, respectively, a sign that the agency is open to approval if the drugs are shown to be effective and safe in trials. The potential market is huge and extremely lucrative, predicted to be valued at $7 billion by 2027, according to an analysis from Data Bridge Market Research.

Psychedelic drugs, though, both exist in nature and have been studied for decades MDMA was first synthesized in 1912 and psilocybin in 1958. This makes it challenging for pharmaceutical companies to follow traditional approaches of patenting newly discovered drugs to protect their investments and fend off competitors. Instead, companies are creating more niche patents, such as Compasss IP on various forms of psilocybin: They need to figure out how to protect this naturally occurring substance, said Citi analyst Neena Bitritto-Garg. (Citigroup has received compensation from atai life sciences, which owns more than 20% of Compass, for investment banking and other services.)

There is also considerable debate and competition within the industry about whether and how these drugs should be patented. Compass is due to publish results from a Phase 2b trial with 233 patients for psilocybin therapy for treatment-resistant depression before the end of this year. Meanwhile, the non-profit Usona Institute, which is anti-patent, is running a Phase 2b psilocybin trial for people with major depressive disorder.

Carey Turnbull, a philanthropist who is a board member of several psychedelic non-profits including Usona Institute, created another non-profit, Freedom to Operate, to fight patents that infringe on existing knowledge. He believes Compasss latest patent should not stand.

From FTOs ongoing research, we understand that it is nearly impossible to crystallize psilocybin and not obtain this hydrate, Turnbull wrote to STAT. There are several examples of it in the prior art. He declined to give details of the existing examples while still putting together a report.

Usona itself is not worried about psilocybin patents affecting its work, said president Bill Linton: The non-profit is using a version of the drug that has been in the public domain since 1958.

Psychedelic patents are currently so turbulent, with waves of applications and challenges, in part because many patent examiners are unfamiliar with the space and the existing research, said Marks. The Usona Institute is currently building out a library of existing research, Porta Sophia Psychedelic Prior Art Library, to help prevent patents being awarded on pre-existing knowledge. Psilocybin was first synthesized in the 1950s and, given the large numbers of laboratories, Marks said hes doubtful there are truly novel formulations left to be patented.

Even among psychedelic patents that meet the technical definition of novelty, the rush to protect formulations simply to block competition, rather than patenting an innovation thats useful to patients, is contrary to the spirit of IP law, said Marks. U.S. patent law technically requires utility, but this is rarely applied in practice: Effectively it doesnt exist. Other countries, such as India, are far more strict about creating patents that are useful for patients, making IP grabs more difficult, as Marks outlines in a forthcoming Harvard Law Review Forum on psychedelic patents.

It could be a patent on something thats useless, said Marks on the Compasss latest patent. I would not make any assumption that it makes any real benefit.

Different formulations of psilocybin could have varying levels of effectiveness, and Wilde of Compass said the company is exploring whether the latest form could be particularly beneficial under certain conditions.

In his view, all patents are beneficial. IP allows companies to protect innovation, and therefore finance research and bring drugs to patients, he said: Any patent therefore is in the interest of patients and more broadly in the interest of the field.

Those pushing back argue that a small number of companies owning the rights to these drugs will make any treatments that are approved more expensive. If the FDA approves psilocybin following Compass Pathways research, for example, only the patented synthetic version of the drug would be legal medicine, rather than the naturally occurring substance. It will affect the barriers to entry for scientific research and the cost to accessing these therapies, said Marks.

For investors, the crucial question is whether patents are approved and withstand challenges. Ethical questions are less of a concern, said Citis Bitritto-Gard: Investors are profit-seeking.

So as psilocybin slowly edges toward approval as a medicine, fights over every line of intellectual property are likely to grow fiercer. The eventual patent decisions will determine who controls the supply of psilocybin, and who profits off this hallucinogenic drug.

Correction: An earlier version of this story misstated the date when psilocybin was first synthesized.

View post:

Psilocybin patent highlights the swirling battle over psychedelics IP - STAT - STAT

The people turning to psychedelics on their deathbeds – The Independent

Thomas Hartle is an unlikely psychedelics adventurer. The 53-year-old father of two from Saskatoon, Canada, describes himself as being about as ordinary and boring as white bread. Until a few years ago, he had never even considered taking any sort of illegal substance. I grew up in the This is your brain on drugs generation, he tells me when we speak over a video call, referring to the notorious anti-drugs campaign launched in 1987 which featured that memorable slogan over the image of an egg frying on a skillet. I considered that whole class of drugs as not just unhelpful, but as something that ruins peoples lives.

In 2016, Hartle was diagnosed with stage four colon cancer. He went through multiple rounds of chemotherapy and radiation treatment, but the cancer returned in August 2019. Faced with the very real prospect of death, he decided to seek out new ways of coping. It was then he remembered research hed come across online, published by Johns Hopkins Medicine in 2016, which suggested (via a small sample of 51 patients) that therapeutic use of psilocybin the active ingredient in magic mushrooms could help decrease depression and anxiety in patients with life-threatening cancer.

Last year, Hartle wrote to Canadas Ministry of Controlled Substances to ask for a legal exemption to try psilocybin for himself. He was one of four patients in the country to be granted permission and became the first Canadian to legally experience a psychedelic therapy session on 12 August 2020. The results were immediate, and measurable. The day before, Hartle had registered 36 on the Beck Anxiety Inventory, on which any score above 25 is considered severe anxiety. The following day, using the same metric, he scored six, considered minimal. I knocked 30 points off my standing level of anxiety, says Hartle, And that really lasted for a very long time.

For Hartle, the benefits of psilocybin therapy went far beyond simply reducing his fear and anxiety over dying. He says he found the experience itself to be a profound one, and that it gave him new belief in the possibility of life after death. My views on death have really changed tremendously, he says. Before, life after death was a sort of academic, intellectual concept, whereas now it feels tangible. Ive physically experienced states of consciousness that have nothing to do with this life or anything that I would identify with Thomas.

Hartle is not alone in reporting this kind of positive response. Laurie Brooks, a 53-year-old from Abbotsford, British Columbia, was another of the original group of four patients granted permission to try psilocybin therapy in Canada last year. She also has colon cancer, and in August 2019 her doctors told her she may only have six months to a year to live. It was then she became interested in psychedelic therapy. If this was it for me, I didnt want to be crying and depressed, she says. So I did my trip, and it was such a profound change. I went from feeling desperate, alone and grief-stricken to the next day feeling as if I were able to see my cancer in a box beside me on the floor. I felt in control, rather than it controlling me, and that made a huge difference. A lot of healing has come from that.

(Getty Images/iStockphoto)

Psilocybin was banned globally as part of the UN Convention on Psychotropic Substances in 1971, primarily for political reasons as psychedelics were considered a destabilising influence whichthreatened established cultural norms. Very little research was done into the potential of psychedelics for the next two decades, but since the early Nineties there have been a resurgence in clinical trials and the approach to psilocybin is now more lenient in some other countries. As well as the compassionate use allowances that gave Hartle and Brooks access to psychedelic therapy in Canada, several areas of the United States have already relaxed legislation around psilocybin. City councils in Denver, Colorado and Oakland, California have both decriminalised magic mushrooms, while in November last year Oregon became the first state to legalise the use of psilocybin for a two-year window for both recreational and therapeutic use.

Psilocybin is a Class A drug in the UK. It is also listed as a Schedule 1 drug under the Misuse of Drugs Regulations (along with substances like MDMA and LSD), which means it cannot be lawfully possessed or prescribed and that a Home Office licence is needed before it can be used in research. Despite the optimistic results of some recent research, sample sizes have been small. Although it is not considered an addictive drug, the potential for a bad trip remains, during which users may experience disturbing hallucinations, panic, delirium and psychosis. Some users may even experience Hallucinogen Persisting Perception Disorder (HPPD), often referred to as flashbacks, involving perceptual changes lasting weeks or months which can require medical attention.

But pressure is growing on governments around the world to allow greater research into psychedelic therapy in general. Campaigners like Conservative MP Crispin Blunt are calling for psilocybin to be moved to Schedule 2, which would enable the drug to be used in scientific and medical research. Last month,Mr Blunt called on Boris Johnsonto cut through the current barriers to research into psilocybin and similar compounds in the UK.

In response, the Prime Minister said only that his government will consider the Advisory Council on the Misuse of Drugs recent advice on reducing barriers to research with controlled drugs such as the one he describes, and we will be getting back to him as soon as possible. British government pronouncements on this subject often resemble a classic Catch-22: They will allow further research only once further research has been done.

Ive interviewed patients who have used psychedelics and what I hear from them is that it allowed them to talk about scary things

Dr Anthony Back, director of palliative care at the Seattle Cancer Care Alliance

These developments have been welcomed by medical professionals like Dr Anthony Back, the director of palliative care at the Seattle Cancer Care Alliance and a professor of medicine at the University of Washington. Dr Back has spent years studying the way that doctors communicate with patients who are at the end of their lives, and believes the current system often fails both parties. After reading the psilocybin research from Johns Hopkins, as well as a similar study at NYU, Dr Back decided to investigate for himself.

I arranged to have an underground experience with psilocybin. That experience made me think: Wow! There is really something to this. It really is a game changer. His own positive experience has been mirrored by the patients hes spoken to. Ive now interviewed a bunch of patients who have used psychedelics, both in studies and underground, and what I hear from them is that it allowed them to talk about scary things, he says. Usually, our defences go up when we try to talk about these subjects. It turns out, unlike what our egos normally think, that actually we arent destroyed if we talk about death. In fact, something really important and even beautiful can happen.

(Getty Images)

Dr Back offers some insight into how psychedelics are able to have such a transformative impact on brain function. One important aspect is that they physically reduce blood flow to whats known as the default mode network. The default mode network is where all of our stories about me are created. Im the kind of person who likes this, Im not the kind of person who does that, explains Dr Back. What psychedelics do is disrupt all those usual little stories that we have about ourselves. All of a sudden, were able to make connections between things that are already in our brains but that arent usually connected. Psychedelics give you a window of time when you can make all these different connections that are outside of your usual habits of thinking. This description rings true to Thomas Hartle, who offers a metaphor. Its the equivalent of fresh, fallen snow, says Hartle. Where all the old pathways used to be, theres now this fresh covering.

Its the equivalent of fresh, fallen snow. Where all the old pathways used to be, theres now this fresh covering

Thomas Hartle

Part of the reason some doctors and patients are so intrigued by psychedelic therapy is that they believe it provides a form of treatment which conventional medicines simply cant offer, as the San Francisco-based physician Dr Shoshana Ungerleider explains. As MDs, when we see somebody anxious or distressed, we prescribe them medicine like a benzo [Benzodiazepines, drugs used to treat anxiety and depression] or an opiate to calm them down or dull their senses, she points out. Weve been doing that for a long time, because those are the sorts of tools we have, but what that also does is blunt your ability to live fully and be present.

Hoping to open conversations about the best ways to improve end-of-life care, Dr Ungerleider founded the non-profit End Well in 2017. She was so impressed by the potential of psychedelics to transform the field that earlier this month she organised The End In Mind, a virtual conference dedicated specifically to the use of psychedelics. From my point of view, the power of these medicines is that we can not only reduce physical pain symptoms, but also the emotional distress that so many people have around this time of life, she says, urging politicians like the Prime Minister to remove the barriers that still stand against further research. I think we have an obligation as a society to really investigate this fully.

See the rest here:

The people turning to psychedelics on their deathbeds - The Independent

Psychable CEO to be Featured Speaker at Microdose Wonderland Conference to Discuss Affordability and Accessibility of Psychedelic-Assisted Therapy -…

Jemie Sae Koo Speak on Making Psychedelic-Assisted Therapy More Accessible

LOS ANGELES, Nov. 01, 2021 (GLOBE NEWSWIRE) -- When Jemie Sae Koo and Matt Zemon founded Psychable, the #1 most trusted and comprehensive online community dedicated to connecting those interested in legally exploring psychedelic-assisted therapy with practitioners in the space, they recognized a need for more access to the transformational power of psychedelic-assisted therapy.

Now, with Psychable boasting over 2,500 practitioners on its platform, CEO Jemie Sae Koo has been tapped to share her vision for the future of psychedelic-assisted therapy in the U.S. and across the world with attendees at Wonderland: Miami by Microdose, the largest psychedelic medicine business event.

Psychable entered the market as a sought-after solution in the mental health space. With legislation surrounding the descheduling and medical legalization of psychedelics taking root across the U.S., an increasing number of people are seeking information on alternative wellness methods and legal paths to pursue them at home and abroad. As a result, Psychable grew quickly into the most trusted and comprehensive online community for those seeking education and treatment in psychedelic-assisted therapy, integration and aftercare.

Wonderland is one of the premiere gatherings for forward-thinking today. Im excited to be a part of this years conference to share our vision on affordability and accessibility of psychedelic medicine with attendees, not only as an entrepreneur in psychedelic wellness, but as someone who had my own transformative personal experience with the healing power of psychedelics, said Jemie Sae Koo, CEO of Psychable. I look forward to sharing the thought process behind our buy-one give-one program with ketamine-assisted therapy, donating a subscription to a veteran, first responder, or member of an underserved community with every new subscription sold.

Sae Koo will be speaking on Psychedelics and the Current Medical Model along with a panel featuring Dr. Geraldine Kuo; Kimberly Juroviesky, President of Ketamine Taskforce; Lynn Marie Morski, President of Psychedelic Medicine Association; Olivia Mannix, CEO of Cannabrand; and Sophie-Charlotte Adler, Psychologist at the Instituto Dr. Scheib.

Story continues

We are honored to be featured alongside of industry and academic leaders including Rick Doblin, Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS); Robin Carhart-Harris, Director, Psychedelic Division of the University of California San Francisco; and Matthew Johnson, Professor of Psychiatry and Associate Center Director of Johns Hopkins University School of Medicine, said Matt Zemon, CSO of Psychable. As the conversation around psychedelic-assisted therapy advances in culture, medicine and legislation, we remain committed to educating people around the world about their treatment options and continuing to foster deep trust within Western and indigenous practitioners in the space.

Sae Koo and Zemon are united in a belief that psychedelics can provide meaningful and transformative treatments for not only those struggling with a myriad of ailments, but also those looking to transform their lives for the better. With both having transformative experiences with psychedelic medicine that led them to pursuing a Master of Science Degree in Psychology with a focus on Psychedelic-Assisted Therapy, theyve curated a team of experts with deep experience to lead the Psychable community to support all phases of the journey from information to integration.

To hear more about Sae Koo and Zemons thoughts on affordability and accessibility during the Wonderland Conference in Miami on November 8th and 9th, tickets are available at https://microdose.buzz/?ref=11669. Enter Psychable20 for a 20% discount.

About Psychable

Psychable is the #1 most trusted and comprehensive online community connecting those who would like to legally explore the healing power of psychedelics with a network of practitioners and psychedelic-based treatments, including integration, psychedelic-assisted therapy, and retreats. Through its ketamine-assisted telehealth therapy offering, and an industry-leading Buy One, Give One model, Psychable provides life-transforming treatment to those in need, including veterans and those in underserved communities.

Psychable was launched in 2021 by Jemie Sae Koo and Matt Zemon, successful entrepreneurs whose transformative experiences with psychedelic medicine led them to each pursue a Master of Science Degree in Psychology with a focus on Psychedelic-Assisted Therapy. Through Psychable, their mission is to transform the lives of millions of people suffering with conditions such as depression, PTSD and addiction, and to empower those who want to live a more optimized life.

The platform is supported by a passionate team of experts in psychology, business, medicine, and law. For more information on our mission and community, visit https://psychable.com/, or follow us on Linkedin, Instagram, Twitter, and Facebook.

Contact: media@psychable.com

Read this article:

Psychable CEO to be Featured Speaker at Microdose Wonderland Conference to Discuss Affordability and Accessibility of Psychedelic-Assisted Therapy -...

Meet Delic Announces Full Lineup of Music, Visual and Performance Artists for Two-Day Immersive Edutainment Experience – Yahoo Finance

Entertainers join world's leading psychedelic and wellness thought and business leaders at Meet Delic, the revolutionary event taking place at AREA15 in Las Vegas, Nevada, November 6 7, 2021

VANCOUVER, BC, Nov. 2, 2021 /PRNewswire/ - Delic Holdings Corp ("Delic" or the "Company") (CSE: DELC) (OTC: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, today released the full entertainment lineup for Meet Delic, the two-day premier psychedelics event. From pop-royalty dance performers and groundbreaking visual experiences to new technologies and research, thought-provoking presentations, and the world's largest psychedelic business expo, there will be something for everyone to explore.

Meet Delic Entertainment Lineup (CNW Group/Delic Holdings Inc.)

Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, wellness, and business with like-minded visionaries. The entertainment lineup spans the worlds of music, visual technology, and performance art and will be joining headliners Lamar Odom, Duncan Trussell, Alyson Charles, Ifetayo Harvey, Dr. Carl Hart, George Goldsmith, Ekaterina Malievskaia, M.D., Zappy Zapolin, Aubrey Marcus and many more for an unforgettable experience:

Little Miss Nasty, November 6 and 7: Beyonc, Justin Bieber, Ariana Grande, Britney Spears, Usher, Katy Perry, Nick Jonas and Lady Gaga. These superstars are only some of the artists on this high-energy dance duo's impressive resume. What started as a "rock and roll burlesque" dance show in Los Angeles has evolved into a performance art group and lifestyle brand with global tours and multiple sold-out residencies in Las Vegas, Long Beach and San Francisco.

Sporeganic, November 6 and 7: Scott Hedstrom, whose pseudonym is Sporeganic, has created spectacular live visual experiences at shows for artists such as The Grateful Dead side project Billy & The Kids, STS9, Android Jones and CloZee. As the Technical Director at Vision Agency, he and his team created the psychedelic visuals tool, Microdose VR, which brings audiences on cinematic journeys through psychedelic landscapes. Hedstrom is focused on building the technology behind the upcoming biofeedback VR experience, Chromadose.

Story continues

DJ David Starfire & Live VJ Jonathan Singer, November 6: This duo will celebrate the legends of psychedelia through a journey of sight and sound during a live tribute featuring the music of The Grateful Dead, The Beatles, Pink Floyd, Jefferson Airplane and Jimi Hendrix. A special live, immersive 360 visual performance set to Pink Floyd's "Set The Controls For The Heart Of The Sun" and Futuristic Psychedelia Dance and Techno themes featuring the music of Tipper, Desert Dwellers and David Starfire will close out the set.

Mindchatter, November 7: New York City-based singer, songwriter and producer Bryce Connolly, who goes by Mindchatter, is known for creating sounds that defy genre and writing lyrics tinged with introspection. His first single "Trippy'' was released in 2019, growing his avid fan base and garnering praise from BBC Radio 1's renowned DJ, Pete Tong. In 2020 Mindchatter debuted his first album, Imaginary Audience, and kicked off his own slate of headlining shows that combine his ethereal beats with one-of-a-kind visual experiences.

Meet Delic is committed to bringing awareness of the science-backed benefits of psychedelics and business opportunities to the mainstream and larger global community by reframing the psychedelic conversation. The twenty hours of panels and keynotes will include an array of topics such as Accelerating Adaptation: What Psychedelic States can teach us about Healing, Aphrodisiacs and Psychedelics: A History of Medicine for Love, Fentanyl in our Drugs, Ketamine: An Intimate Discussion on the New Wonder Drug for PTSD, Deciphering the Medical Potential of Psychedelics, A Discussion with George Goldsmith & Ekaterina Malievskaia featuring Clara Burtenshaw, Psychedelics and Futurism.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook.

Meet Delic is a subsidiary of Delic, which is focused on addressing the mental health crisis by bringing psychedelic wellness to the mainstream. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) the nation's largest and most accessible network of psychedelic wellness clinics to administer effective treatments 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines and 3) trusted media and e-commerce platforms and in-person events like Meet Delic to market the services directly to patients and consumers and gain data.

About Meet DelicMeet Delic is the world's premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement.

About Delic CorpDelic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, including Ketamine Infusion Centers and Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved".

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

Meet Delic logo (CNW Group/Delic Holdings Inc.)


View original content to download multimedia:https://www.prnewswire.com/news-releases/meet-delic-announces-full-lineup-of-music-visual-and-performance-artists-for-two-day-immersive-edutainment-experience-301413583.html

SOURCE Delic Holdings Inc.

Continue reading here:

Meet Delic Announces Full Lineup of Music, Visual and Performance Artists for Two-Day Immersive Edutainment Experience - Yahoo Finance

Breaking the Habit: Psychedelic Stigma Fades as Research Points to Critical Use in Smoking Cessation and More – PRNewswire

NEW YORK, Nov. 1, 2021 /PRNewswire/ -- There isn't a cigarette smoker in the world who doesn't know smoking is bad for them. The problems are that nicotine is one of the most highly addictive substances in the world, and for the nearly 70% of 34.1 million Americans who want to kick the habit, there aren't many smoking-cessation options that have proven safe and effective. Hope may be looming on the horizon, however, with new research building on prior studies that suggest psilocybin is not only a potential solution but also a more effective one. Leading a charge on this front is Mydecine Innovations Group(NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (Profile), a biopharmaceutical firm formed in 2020 for the purpose of developing innovative therapeutics to treat PTSD, depression, anxiety, addiction and other mental health disorders. Mydecine is part of a renaissance for psychedelic medicine research that is showing real promise in addressing areas of unmet medical need. Those contributing to the resurgence includes peers such as COMPASS Pathways Plc(NASDAQ: CMPS), ATAI Life Sciences N.V.(NASDAQ: ATAI), Cybin Inc.(NYSE American: CYBN) and Field Trip Health Ltd.(NASDAQ: FTRP).

Click hereto view the custom infographic of the Mydecine Innovations Groupeditorial.

Chantix Recall Leaves $1 Billion Up for Grabs

According to the Centers for Disease Control and Prevention, cigarette smoking is responsible for one of every five deaths in the United States annually, while the World Health Organization estimates tobacco-use costs at more than $1.4 trillion in health expenditures and lost productivity each year. It's not that people don't want to quit smoking; many do. CDC data shows that 55% of smokers have tried to quit, but only about 7.5% succeed.

The desperation for anti-smoking products is exemplified by the drug varenicline (brand name Chantix), which became a blockbuster with 2019 sales of $1.1 billion despite serious psychiatric side effects. Ultimately, Chantix was recalled in 2021, not for the psychiatric adverse events but for "theoretical potential increased cancer risk."

Perhaps new treatments involving psilocybin, the active psychedelic ingredient in "magic" mushrooms, will fill that $1 billion void. A small study by Johns Hopkins University published in "Journal of Psychopharmacology" compared smokers trying to quit using cognitive behavioral therapy (CBT) plus varying doses of psilocybin to abstinence rates typically observed in smokers using other medications or CBT alone. The results showed 67% of the participants remained nicotine free at a 12-month follow-up, a substantial increase over success rates for other methods (typically 10% to 35%).

The study concluded that the "results suggest that in the context of a structured treatment program, psilocybin holds considerable promise in promoting long-term smoking abstinence." Johns Hopkins is conducting a larger efficacy study with compelling data to date, and this month received the first National Institute of Health (NIH) grant in more than 50 years to directly investigate the therapeutic effect of psilocybin for tobacco addiction.

Mydecine Innovations Group(NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA)is an integral part of this landmark NIH-funded research led by Johns Hopkins, a three-year, multisite smoking cessation study being conducted in collaboration with University of Alabama at Birmingham and New York University. Mydecine will be supplying its lead drug candidate, MYCO-001 (99% pure psilocybin), for use in the clinical trials. The supply agreement, in the words of Mydecine CEO Josh Bartch, "not only offers a significant opportunity to further advance our drug development through safer and more viable results but demonstrates Mydecine's leadership position in the emerging psychedelic-assisted psychotherapy industry."

The joint work on the new clinical trial builds upon the budding relationship between Mydecine and Johns Hopkins, considered the top university for psychedelic research globally. Denver-based Mydecine was already working with the team of Dr. Matthew Johnson, a psychedelics authority and professor of psychiatry and behavioral sciences at Johns Hopkins, on smoking-cessation projects using psychedelics. In August that partnership parlayed into a five-year master collaboration research agreement to look at several novel therapies and compounds for the treatment of a multitude of mental health and addiction disorders. Johnson is the lead on the upcoming NIH-funded trials and will be lending his expertise to other upcoming clinical studies by Mydecine.

Catalyst: Clinical Trials for MYCO-001

Clinical trials are milestones and catalysts for biopharma companies, and Mydecine is staring at three of them in 2022 for MYCO-001. First is the NIH-funded, multicenter study. Second is a company-sponsored seamless phase 2/3 clinical trial also evaluating the administration of MYCO-001 with a structured smoking-cessation treatment program in nicotine-dependent individuals. The trials will run concurrently, and Johnson will be serving as principal investigator in both trials.

Encouraged by FDA commissioner Dr. Scott Gottlieb in 2017 to speed up drug development, a "seamless" clinical trial utilizes an adaptive design to combine two or more traditional phases of the FDA process, which can save not only considerable time but also significant money. Mydecine anticipates its investigational new drug (IND) meeting with the FDA this quarter and to commence another study in January 2022. The study protocol is expected to involve treating participants weekly in one-on-one sessions for five weeks prior to quitting smoking. Primary endpoints will be smoking abstinence at three, six and twelve months.

ResearchandMarkets.com estimates the global smoking cessation market to be growing 16.9% annually to reach $63.99 billion by 2026. The rapidly expanding market and room for new products to capture significant share likely underscore Roth Capital analyst Elemer Piros initiating coverage on Mydecine with a Buy rating and C$3 price target.

PTSD in Veterans, EMS and Front-Line Workers

The master collaboration agreement with Johns Hopkins demonstrates Mydecine's commitment to advancing psychedelic medicine by exploring multiple molecules and medicines for a variety of indications. One of the first targets is post-traumatic stress disorder (PTSD) in veterans, emergency medical service (EMS) and front-line workers.

Currently there are no medications that have been developed to treat PTSD, and those that are prescribed to treat the symptoms can be addictive and often have unpleasant side effects. Mydecine is expecting an IND meeting with the FDA this quarter and plans to start a Phase 2a study involving veterans with PTSD during January 2022 spanning three U.S. sites, two Canadian sites and one in the Netherlands.

A Holistic Approach: MYCO-003 and Mindleap

While those trials progress, Mydecine has three other flagship drug candidates in the pipeline, including MYCO-003, a psilocybin formulation that combines a serotonin agonist with a serotonin-releasing agent. Fact is, a "bad" trip is a possibility when ingesting psilocybin, which requires supportive care from the attending physician. The risk can be exacerbated by patients with high anxiety or PTSD, which Mydecine believes it can mitigate without the need for extensive supportive care through its novel formulation. The company has recently reported positive preclinical data on MYCO-003 and filed a patent application as an anxiety-reducing product.

Many people receiving psychedelic therapy refer to the experience as spiritual, religious, mystical and the like, which gets to the breakthrough opportunity of the treatment by addressing the root cause in the brain rather than putting a Band-Aid on the surface.

Healing and meaningful change are processes that are part-and-parcel to psychedelic regimens. Mindleap Health, a unit of Mydecine, supports this journey as an inner wellness application and community that provides tools for self-discovery. Mindleap offers a comprehensive platform that introduces users to psychedelic integration, dream analysis and deepening awareness with top experts as a part of a holistic, real healing approach.

Investors Cheer as Evidence Mounts

Decades ago, a growing body of evidence highlighted the potent therapeutic effect of psychedelic compounds for hard-to-treat diseases. Some 51 years after President Richard Nixon signed the Controlled Substance Act that stymied R&D work with psychedelics, those same diseases remain pervasive and resistant to traditional therapies. While more clinical studies will lend further indubitable data, that work is gaining steam.

COMPASS Pathways Plc(NASDAQ: CMPS) is a mental health-care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is pioneering the development of a new model of psilocybin therapy, in which its proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a breakthrough therapy by the FDA for treatment-resistant depression, and COMPASS is currently conducting a phase IIb clinical trial of psilocybin therapy for TRD in 22 sites across Europe and North America.

ATAI Life Sciences N.V.(NASDAQ: ATAI)is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018, atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics with a focus on psychedelic therapies to treat depression, anxiety, addiction, and other mental health disorders. Most recently, its DemeRx IB business announced that the first subjects have been dosed in a Phase 1/2a clinical trial of ibogaine HCl (DMX-1002) for opioid use disorder.

Cybin Inc.(NYSE American: CYBN)is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. In its bid to create a world-class portfolio of psychedelic molecules that can become commercially viable drug candidates for internal development or partnering, Cybin this month completed 74 in-vitro and in-vivo evaluations of its expanding portfolio of psychedelic compounds. To date, more than 50 novel compounds have been evaluated through collaborations with experienced contract research organizations.

Field Trip Health Ltd.(NASDAQ: FTRP)is the global leader in the development and delivery of psychedelic therapies. The company's Field Trip Discovery division is focused on the development of next-generation psychedelic molecules and is conducting advanced research on plant-based psychedelics; its Field Trip Health division is opening centers for psychedelic therapies across North America and Europe.

Thanks to strong investor appetite and hundreds of millions of dollars in funding, psychedelic research is accelerating and clinics making the treatment readily available are cropping up all over the world. The days of viewing psychedelics as merely amusements of counterculture are fading and, for the first time in a long time, it feels like the world is closing in on a new psychedelic-based therapy to fill gaps where traditional drug makers have failed.

For more information about Mydecine Innovations, please visit Mydecine Innovations Group.

About NetworkNewsWire

NetworkNewsWire("NNW") is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork("IBN"), that provides: (1) access to a network of wire solutions via NetworkWireto reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)

For more information, please visit: https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:http://NNW.fm/Disclaimer

NetworkNewsWire is part of theInvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with NNW or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW and FNM for any investment decisions by their readers or subscribers. NNW and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.


This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW and FNM undertake no obligation to update such statements.

Corporate Communications Contact:

NetworkNewsWire (NNW)New York, New Yorkwww.NetworkNewsWire.com212.418.1217 Office[emailprotected]

Media Contact:

FN Media Group, LLC[emailprotected]+1-(954)345-0611

SOURCE NetworkNewsWire

More here:

Breaking the Habit: Psychedelic Stigma Fades as Research Points to Critical Use in Smoking Cessation and More - PRNewswire

North America Continues Leading The Way In Psychedelic Wellness – PRNewswire

PALM BEACH, Fla., Oct. 26, 2021 /PRNewswire/ --FinancialNewsMedia.com News Commentary- The global psychedelic drugs market remains at an early stage in its life cycle, with most companies currently developing their go-to-market strategy. The market players of psychedelics are involved in the clinical trials of several psychedelic drugs to address mental health, which continues to present significant unmet need.For the behavioral health industry, psychedelics present an opportunity to potentially bolster providers' treatment toolbox and help patients for whom current psychiatric medications have failed. While it's unclear exactly what the future of psychedelics in the U.S. behavioral health industry will look like, Canadians are looking at a clearer picture. When it comes to psychedelic wellness, Canada is leading the way, accordingto Behavioral Health Business. They said: Regulations were recently relaxed there to make it easier for alternative medicine companies to develop psychedelic behavioral health treatments.Those newfound flexibilities are similar to right-to-try laws in the US, which allow terminally ill patients to use experimental therapies that have passed Phase I in the U.S. Food and Drug Administration's approval process.The difference, however, is that only one state in the US along with several municipalities has authorized exemptions for psilocybin; meanwhile, all 13 Canadian provinces and territories currently have exemptions for the psychedelic substance often used as a source for alternative behavioral health treatments." Active Companies active today in markets include: Cybin Inc. (NYSE: CYBN) (NEO: CYBN), COMPASS Pathways plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), Eli Lilly and Company (NYSE: LLY), Johnson & Johnson (NYSE: JNJ).

Under the care of a clinician, patients using psilocybin for behavioral health treatment typically receive the psychedelic drug to treat conditions like stress, anxiety and depression, especially for patients who have not had success using other treatments or are facing terminal illnesses. As with the US, possession of psilocybin mushrooms in Canada is illegal. However, last August, Health Canada the country's regulatory health body approved the use of psilocybin to treat four terminally ill patients for anxiety, stress and depression.Several months later, in December,Health Canada also approved exemptions to a group of doctors and therapiststo use psilocybin for research purposes, allowing them to study its effects on patients in hopes of developing therapies for future use. As a result, British Columbia which is also home to a number of Canadian cannabis companies has become a hotbed for psychedelic wellness startups.

Cybin Inc. (NYSE AMERICAN: CYBN) (NEO: CYBN) BREAKING NEWS: Cybin Announces FDA Investigational New Drug Authorization of Cybin's Sponsored Feasibility Study using Kernel Flow Technology - Cybin Inc. ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that the U.S. Food and Drug Administration ("FDA") has authorized an Investigational New Drug ("IND") application to proceed with the Company's sponsored feasibility study using Kernel's Flow technology to measure ketamine's psychedelic effect on cerebral cortex hemodynamics.

"The word psychedelic means 'mind-manifesting,' but what has been missing is useful 'mind-imaging'the ability to dynamically trace the neural correlates of human conscious experience. Conventional neuroimaging just isn't dynamic enough to study the psychedelic experience in the brain as it happens. This study of ketamine's psychedelic effects while wearing headgear equipped with sensors to record brain activity could open up new frontiers of understanding," said Dr. Alex Belser, Cybin's Chief Clinical Officer.

Leveraging Kernel's quantitative neuroimaging technology ("Kernel Flow") may lead to new frontiers in psychedelic therapeutics by enabling the acquisition of longitudinal brain activity before, during and after a psychedelic experience, providing quantification of what was previously subjective patient reporting.

"Quantitatively measuring the brain within the context of a psychedelic experience is a promising frontier," said Bryan Johnson, founder and Chief Executive Officer of Kernel. "With Kernel Flow, Cybin's researchers can start putting numbers and quantification to subjective states of mind, including altered ones."

Kernel Flow uses pulsed light instead of continuous wave light to increase measured brain information. In contrast with electroencephalography ("EEG") electrodes that usually require gel on the head or functional magnetic resonance imaging ("fMRI") studies that require a participant to lie in a scanner, Kernel Flow is easily wearable. The entire system is the size and look of a bicycle helmet and could, in the future, be more broadly used for neuroscientific or physiological studies of brain activity during psychedelic use.

As part of Cybin's sponsorship of the feasibility study, the Company will retain an exclusive interest in any innovations that are discovered or developed through its independent analysis of the study findings. Kernel will hold the same rights relating to its Kernel technology. CONTINUEDRead the full Press Release for Cybin at: https://www.cybin.com/news

In other active company biotech news in the markets this week:

COMPASS Pathways plc (NASDAQ: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, recently welcomed the topline data shared from an open-label study of psilocybin therapy for depression in cancer patients. Within one week of a single administration of COMP360 psilocybin therapy, 50% of participants achieved remission in depression symptoms, which was sustained for the eight week follow-up period.

This investigator-initiated feasibility study was conducted by Maryland Oncology Hematology at the Aquilino Cancer Center in Rockville, Maryland, USA. It was an open-label study involving 30 patients with cancer diagnosis and major depressive disorder (MDD), all of whom completed the study. Half of the participants had previously been treated for their current episode of depression with antidepressants and all were receiving active treatment for cancer; 19 participants had no previous experience with psychedelic substances. Patients were given a 25mg dose of COMP360 psilocybin in conjunction with psychological support from specially trained therapists, following the COMP360 psilocybin therapy protocol.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a leading biotech company developing psychedelic-inspired therapies, recently announced that Dr.Matthias Liechtipresented data from several ongoing studies at the INSIGHT Conference inBerlin, Germany. These investigator-initiated studies are being conducted as part of MindMed's ongoing collaboration with the UHB Liechti Lab.

"While both LSD and psilocybin have a long history in psychiatric research, psilocybin is being studied in a majority of ongoing clinical trials of psychedelics," said Dr. Liechti. "It is important for us to understand the acute effect characteristics of different psychedelics, and to understand how these substances interact with other treatments like antidepressants. We look forward to fully analyzing the exciting data produced by these studies and publishing our findings later this year."

Eli Lilly and Company (NYSE: LLY) recently announced the board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2021 of $0.85 per share on outstanding common stock.

The dividend is payable on December 10, 2021 to shareholders of record at the close of business on November 15, 2021.Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Johnson & Johnson (NYSE: JNJ) The Janssen Pharmaceutical Companies ofJohnson & Johnson(Janssen) previously announced the submission of a New Drug Application (NDA) to theU.S. Food and Drug Administration(FDA) for esketamine nasal spray. Janssen is seeking FDA approval of esketamine for treatment-resistant depression in adults.

Esketamine is an investigational, rapidly acting antidepressant that works differently than currently available therapies for major depressive disorder. Through glutamate receptor modulation, esketamine is thought to help restore connections between brain cells in people with treatment-resistant depression.

"Of the nearly 300 million people who suffer from major depressive disorder worldwide, about one-third do not respond to currently available treatments.3,4This represents a major unmet public health need," saidMathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. "We are committed to working with the FDA to bring this new treatment option toU.S.patients with treatment-resistant depression and to the medical community."

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated twenty six hundred dollars for news coverage of current press release issued by Cybin Inc.by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:Media Contact email: [emailprotected] +1(561)325-8757

SOURCE FinancialNewsMedia.com

Read the rest here:

North America Continues Leading The Way In Psychedelic Wellness - PRNewswire

Someone is selling psychedelics with a Squid Game poster in Vancouver | News – Daily Hive

As some local businesses lean into Squid Game business cards to advertise their products, at least one online retailer of psychedelics is jumping on the trend.

Daily Hive spotted a Squid Game-themed poster at West Cordova Street and Cambie Street Wednesday morning, just outside the Woodwards building.

The poster links to Area 51, an online store that sells mushrooms, LSD, DMT, MDMA, and ketamine. Daily Hive has reached out to the store for comment.

Daily Hive

The shop only accepts Bitcoin because, according to its website, PayPal closed its account. It also says its been selling these products online for over a year.

The gory Korean drama quickly became Netflixs most-viewed show ever this month. Other businesses, including a local radio show and a workout supplement shop, have placed Squid Game-style business cards on vehicles around the Lower Mainland.

While those businesses were selling legal wares, this shop sells controlled substances although, according to its website, it has as close to a perfect record as possible in the industry.

Several other psychedelic shops have been putting scannable QR code posters up around downtown recently, but their graphics tend to be mushroom-themed rather than reminding potential customers of the chilling show.

One thing is for certain nobody wants their trip to turn out like Squid Game.

View post:

Someone is selling psychedelics with a Squid Game poster in Vancouver | News - Daily Hive

Brain stimulation, neurofeedback, and the promise of enlightenment now – Vox.com

It was a Monday morning, which was reason enough to meditate. I was anxious about the day ahead, and so, as Ive done countless times over the past few years, I settled in on my couch for a short meditation session. But something was different this morning.

Gently squeezing my forehead was a high-tech meditation headset, outfitted with sensors that would read my brain waves to tell me when I was calm and when I was, well, me. Beside me, my phone was running an app that paired over Bluetooth with the headset. It would give me audio feedback on my brains performance in real time, then score me with points and awards.

This was the Muse headband, an innovation in mindfulness that picks up on Silicon Valleys penchant for quantifying every aspect of ourselves through wearable tech the idea being that the more data you have on your brain waves, heart rate, sleep, and other bodily functions, the more you can optimize the machine that is you. But a thought nagged at me: Isnt there something self-defeating and contradictory about trying to optimize meditation by making it all about achieving success in a gamified app?

The underlying technology is definitely intriguing. Muse is an application of neurofeedback, a tool for training yourself to regulate your brain waves. Neurofeedback began gaining popularity years ago in clinical contexts, as research showed it had the potential to help people struggling with conditions like ADHD and PTSD.

Muse is one of several companies now selling neurofeedback devices with a different aim: making you a more enlightened version of yourself. At $245 a pop, its headbands are already accessible to consumers at stores like Walmart or Best Buy.

In fact, neurofeedback is just one of the newer technologies being touted as a way to catapult us into higher, more enlightened states of consciousness. Other technoboosts include brain stimulation, which uses electric currents or other means to directly target certain brain areas and change their behavior, and synthetic psychedelics, which are lab-created versions of drugs such as ayahuasca. Collectively, they form a genre that Kate Stockly and Wesley Wildman, researchers at Boston Universitys Center for Mind and Culture, call spirit tech.

Like me, the researchers started out skeptical of these technologies. But they grew fascinated as they began exploring big questions: Can we use tech to provoke experiences that will make people lastingly more compassionate and altruistic? Is an experience of enlightenment thats induced by technology authentic (and does that matter)? If we democratize spiritual insights so they become accessible faster to lots more people not just those of us who can afford to spend decades meditating in a cave somewhere can that help our species evolve?

These questions, and the shifting answers to them, hint at the strange new terrain we are wandering onto, as neuroscience, self-optimization tech, and mindfulness collide.

The different varieties of spirit tech neurofeedback, brain stimulation, and synthetic psychedelics most prominently all have the same general objective of abetting a persons search for a higher state of consciousness. But they all have their distinct ways of getting you there.

Neurofeedback devices for meditation aim to help you get into a state of calm, focused attention by tracking your brain activity and producing guiding sounds to let you know when your mind is wandering.

There are a few different ways this can work, but Ill stick to Muse for illustrations sake. You start by placing a headband on your forehead. Its built-in EEG sensors read your brain waves as you meditate. Some brain waves are associated with focused attention and others are associated with mind-wandering and stress; Muses algorithm picks them apart in real time and offers up a different cue on the phone app depending on what your mind is doing.

When your thoughts are racing, you hear loud rainstorms. Thats your cue to go, like, Oh shit! Im thinking about the grocery list again! Back to meditation! Ariel Garten, the co-founder of Muse, told me.

When your thoughts are calmer, you hear quieter weather. And when you manage to sustain a deep calm for a while, you hear the rewarding sound of birds chirping.

Its a classic Pavlovian-type reinforcement, according to Garten, meant to encourage your brain to remember the feel of this tranquil mental state and return to it over and over. Its also (for better or worse) an ego boost. When the Muse app shows you your stats at the end of a session, you might find yourself thinking: Im crushing this. I got five birds!

Some scientific research indicates that neurofeedback can modestly improve attention and subjective well-being. But its important to note that this kind of tech can, at most, help people get to an entry-level state of meditation what you might call, simply, concentration. Researchers do not claim to have figured out how to lead people into more advanced meditative states yet.

Stockly, who tried neurofeedback herself as part of her research for Spirit Tech, the book she co-wrote with Wildman, told me the technology holds promise as a way to shorten peoples meditation learning curve. I could tell when my brain was doing the right thing because I would hear the sound that was supposed to be the positive feedback, she said. She also told me neurofeedback is just the tip of the iceberg. It could be understood as a starter technology on your way to something a little bit more invasive, like brain stimulation.

If neurofeedback devices like Muse only aim to read whats happening in your brain and give you cues that reflect it, then another technique, brain stimulation, aims to write to the brain that is, to directly change what your neurons are up to.

Heres the basic idea: Different states of consciousness manifest in your brain as different patterns of electrical activity, or neurological signatures. Researchers have already figured out what some of them look like. Now, theyre figuring out how to technologically stimulate your brain into those states. Theyre experimenting with a few types of stimulation electric, magnetic, light, and ultrasound to target particular brain areas.

Shooting electricity into your skull might sound painful, but it can be very gentle. There are already a few neurostimulation devices on the market, like Zendo, which come in the form of small pads or patches that you apply to your forehead; they create a tingly sensation as they send low levels of electricity into your brain. They claim to make meditation easier and reduce stress.

The scientific evidence on their efficacy is mixed. Safety-wise, theyre not required to have FDA approval since theyre not marketed as medical devices, but theyre generally considered low-risk for short-term use given that a number of stimulation methods are already approved for clinical use in treating conditions like depression. However, we lack data on the long-term effects of using neurostimulation devices continually.

Meanwhile, some researchers are pursuing a much more ambitious goal than mere stress reduction. Theyre exploring brain stimulations potential to act as a shortcut to enlightenment.

Evan Thompson, a University of British Columbia professor who specializes in Asian philosophical traditions, notes that its inaccurate to talk about enlightenment as if its one monolithic thing. Instead, we have to talk about specific enlightened states. Enlightenment means different things to different teachers, schools, and historical periods, he said. It can mean the elimination of all craving and attachment, for example, or the dissolution of the sense of a separate self.

The latter is particularly relevant to Shinzen Young and Jay Sanguinetti, co-directors of the Sonication Enhanced Mindful Awareness (SEMA) lab at the University of Arizona. Theyve found that beaming ultrasound pulses at a certain brain area, the basal ganglia, leads to a quieting of the ego a less self-focused state of mind.

Young, a monk whos been meditating for 50 years, let his neuroscientist colleague Sanguinetti administer the ultrasound pulses on him. Afterward, he said it accelerated and deepened his ability to enter a state of equanimity and selflessness. In fact, he said it triggered one of the most significant meditations hes ever had. Twelve other advanced meditators later reported similar effects.

Of course, thats not enough to get a sense of whether its truly safe and effective, especially for long-term use. Theres still a lot more safety and efficacy research to be done before brain stimulation using ultrasound will be available outside of specialized labs.

Its not a consumer device package in Best Buy, Garten said. Its far, far, far from being that. Probably 20 or 30 more years.

In the meantime, other researchers are exploring psychedelics, which are undergoing a renaissance these days as their therapeutic potential for treating conditions like depression becomes increasingly recognized.

Many psychedelics, such as magic mushrooms and mescaline, are naturally occurring. But scientists are now busy creating synthetic versions of drugs, like pharmahuasca (synthetic ayahuasca), so the chemical components can be precisely predicted and customized. These drugs dont just read whats happening in the brain; like neurostimulation, they write to it directly.

Scientists have found that psychedelics can produce mystical experiences that lead to lasting changes in tolerance and openness. One study found that regular users of ayahuasca, for example, score higher than nonusers on measures of self-transcendence. Pharmahuasca has produced very similar effects, though research suggests some of the emotional benefits of traditional ayahuasca rituals may be lost when the drug is consumed outside its ceremonial context, perhaps because the intentions of the users are different.

Although some mental health professionals already use synthetic psychedelics in their clinical practices to treat patients, dont expect to see such substances becoming legally available for self-directed use as spirit tech in the US anytime soon. Currently, Americans who want to legally try a drug like ayahuasca (natural or synthetic) have to be members of specific religious communities such as the Native American Church, or else travel to South America. That said, Wildman and Stockly report that there is an active underground market for synthetic psychedelics like pharmahuasca.

When people first hear about technoboosts for enlightenment, theres a tendency to think that using technology to induce spiritual experiences is a totally new phenomenon and that therefore a tech-induced experience is not authentic spirituality.

Thompson says both those premises are wrong. For one thing, people have been using tech to induce altered states of consciousness for millennia. We may not be used to thinking of tools like prayer wheels, mandalas, rosaries, or rhythmic drumming in shamanic dances as spiritual technologies, but thats exactly what they are.

Plus, Thompson told me, I think authenticity is a very misleading concept.

Historically, theres no consensus, even within a single religious tradition, about how to tell a genuine spiritual epiphany from a counterfeit.

Some believe a spiritual experience must be spontaneous to be authentic. Others believe just the opposite that an authentic experience comes about only after someone spends lots of time and effort developing a practice.

As Stockly and Wildman write in Spirit Tech, Some people sense that it just cant be right that spiritual wisdom and experiences that are incredibly hard-won are just suddenly conferred on any old doofus without the exertion of effort, discipline, and commitment.

Likewise, some groups say a spiritual experience is trustworthy if it supports their preexisting, canonical beliefs, and untrustworthy if it produces heterodox beliefs. But others say an experience is authentic precisely if it transcends convention just think of how Jesus taught something new and different from the Judaism of his time.

Stockly, Wildman, and Thompson all told me they think it makes less sense to look at the causes or content of an experience than to look at its consequences. Another way to put this is: Dont ask whether an experience is authentic; ask whether its beneficial. Does it make you more cruel, haughty, and self-centered? Or more compassionate, humble, and other-focused?

A related concern about some technoboosts is that perhaps they only lead to temporary changes altered states, but not altered traits. If their consequences fade away within hours or days, how much good does that really do?

It is possible just to have experiences that are something like transitory highs, Wildman told me. But they can incentivize you to develop a continuous practice. These incredibly powerful experiences can completely change your willingness to take on something like that.

Stockly noted that technoboosts like neurofeedback and brain stimulation are not meant to be one-and-done. Instead, we should think of them as training wheels for the brain. The idea is that it really is targeting the desired part of the brain in such a way that with repeated use, it will actually change the brain, she said. It will help to create those new neural pathways.

Thompson, for his part, worries that such technoboosts might be counterproductive rather than beneficial if, for example, the way the technology mediates the experience of meditation reinforces the ego tendencies that meditation is meant to alleviate. This is his concern about all the gamification the Muse app displays, from telling you when youve achieved a streak of consecutive days to rewarding you with bird chirps when youve stayed calm long enough.

It builds up a sense of a performative, successful self, he said. Like, Oh look, Ive meditated a hundred days in a row now! Its not only distraction, it actually reinforces precisely the thing that youre trying to get beyond.

Garten told me that this was a design question she struggled with a lot. But ultimately, she thinks you need some gamification to motivate the user to keep coming back, at least at first. And even though the birds may be distracting and ego-inflating initially, she thinks they can gradually teach the user an important lesson: equanimity. Get too excited about the appearance of a bird, and it vanishes immediately, because your excited brain state means youve lost the calm that hastened its arrival. In this way, you learn not to get overly invested in any outcome.

That hasnt been my experience with Muse yet. So far, for me, the birds feel like theyre harming rather than helping my practice. But Ive been meditating for about five years. Conceivably, for a beginner, the motivational benefits of gamification, together with Muses ability to show the novice meditator when theyre doing it right, could outweigh the costs.

Theres a less obvious risk we need to bear in mind. Instead of only asking, What if the tech doesnt work as advertised? we also need to ask, What if it does?

On the one hand, that would be exciting. In 2005, the Dalai Lama was asked what he thinks about the possibility of tech leading to spiritual awakenings. He said: If it was possible to become free of negative emotions by a riskless implementation of an electrode without impairing intelligence and the critical mind I would be the first patient.

But most of us do not have the Dalai Lamas training. Sudden, intense epiphanies that powerful new technology like brain stimulation aims to provoke may not have the positive effects you might expect. Normally, people build up to those epiphanies over years of practice or on long meditation retreats; the gradualness of the learning curve and the presence of mentors can help a person integrate an epiphany into their self-understanding. Spirit tech wants to offer a shortcut to gin up epiphanies on-demand and la carte and the effects could be jarring.

As Sanguinetti says in Spirit Tech, If youre a father and you have two children, what does it mean to change you [with brain stimulation]? Because you still need to be able to take care of your children and be motivated to do that. So we dont want to make you happy-detached, we want to make you happy-embodied and a happy, better human being in your society and the specific sociocultural context that youre in.

In traditional spiritual communities, the spirit tech isnt just the meditation you do or the mushroom you ingest. There are mentors and traditions that shape how you make meaning out of a peak experience and integrate it into your humdrum life these are technology, too. Similarly, we may need a cadre of trained people who can guide us through the process of implementing powerful new tools like brain stimulation.

Absent such a framework, Thompson remains unconvinced of the potential of such technologies.

It strikes me as more consumerist, capitalist appropriation of meditation as a kind of narcissistic personal experience, he said. Its about my enlightenment attained through techno-enhancement. Call that enlightenment if you want, but enlightenment in a richer sense is about a profound transformation not of yourself just as an isolated individual but of your relationship to other human beings in the world. Its social.

Reporting for this article was supported by Public Theologies of Technology and Presence, a journalism and research initiative based at the Institute of Buddhist Studies and funded by the Henry Luce Foundation.

Excerpt from:

Brain stimulation, neurofeedback, and the promise of enlightenment now - Vox.com

Mike Tyson says psychedelics saved his life, now he hopes they can change the world – Reuters

During his reign as heavyweight champion of the world, no one was more feared than Mike Tyson, who obliterated opponents with ruthless efficiency.

But all the while, the troubled superstar was at war with himself, battling an abusive voice in his battered head that led "Iron Mike" to the brink of suicide.

He said that all changed when he began taking psilocybin mushrooms, more commonly known as "magic mushrooms," and other similar consciousness-altering substances.

Now the boxing prodigy from Brooklyn is experiencing a career renaissance that he said is the result of psilocybin-powered mental and spiritual exploration.

"Everyone thought I was crazy, I bit this guy's ear off," an upbeat Tyson told Reuters, referring to his infamous 1997 fight against Evander Holyfield.

"I did all this stuff, and once I got introduced to the shrooms ... my whole life changed."

To be sure, many people have had negative experiences with psilocybin, which can cause disturbing hallucinations, anxiety and panic. Medical professionals studying them warn against self-medicating or using them outside of an approved medical framework.

But Tyson, who turns 55 next month, and impressed in his November exhibition bout against Roy Jones Jr, said he has never felt better.

"It's scary to even say that," said Tyson, who is also a cannabis entrepreneur and podcast host.

"To think where I was - almost suicidal - to this now. Isn't life a trip, man? It's amazing medicine, and people don't look at it from that perspective."


Humans have been ingesting psychedelics since the earliest days and as stigmas slowly dissolve, it is beginning to be taken seriously as a psychiatric medicine.

There is still much to learn.

Enter former NHL enforcer Daniel Carcillo, who was nicknamed "Car Bomb" for his violent approach to the sport.

After 164 fights, thousands of hits and at least seven concussions, the two-time Stanley Cup champion was forced to retire in 2015 due to repeated head trauma.

Like Tyson, he was at war with himself and struggling to connect with his wife and young children after his retirement at age 30.

He said psilocybin helped him bridge that gap and the experience led him to found Wesana Health, a first-of-its-kind company dedicated to studying its ability to treat traumatic brain injury (TBI) in athletes, veterans and others.

Wesana recently entered into a clinical research project with the World Boxing Council (WBC) to examine the potential of psilocybin to help boost the brain health of boxers, and Carcillo says he is proof that it works.

"I am cured, for sure, of TBI and any related symptoms. 100%," Carcillo said.

"I do not suffer from slurred speech, headaches, head pressure, insomnia, impulse control issues, anxiety, depression or suicidal ideation," he said.

"I do not suffer from any of that (anymore)."

Carcillo and his team are hopeful psilocybin will become an FDA-approved drug to treat TBI.


Tyson said he wants to spread word of the benefits of psilocybin as widely as possible, which is why he has partnered with Wesana.

"I believe this is good for the world," said Tyson, who said he thinks its use could also help create a more empathetic and just society.

"If you put 10 people in a room that don't like each other and give them some psychedelics, they'll be taking pictures with each other," he said.

"Put 10 people in a room who don't like each other and give them some liquor, and they'll be shooting everybody. That's real talk.

"(Wesana) was on the same level of thinking that I was. They wanted to share this with the world. This is very limited, us doing this in these small ceremonies.

"It needs to be open to the world."

Our Standards: The Thomson Reuters Trust Principles.

Read more:

Mike Tyson says psychedelics saved his life, now he hopes they can change the world - Reuters

Are psychedelics the whole answer? | MHT – Mental Health Today

Psychedelic drugs such as psilocybin, used in combination with talking therapy, are opening new avenues of possibility within mental health care by offering a very different mechanism of treatment from existing psychiatric medications. By inducing a unique state of consciousness, these drugs temporarily alter peoples perception of themselves and their experiences.

This altered state of consciousness creates a window of opportunity by allowing thought processes and perceptions to occur in novel ways, which can enable people to approach their problems from a new perspective. Creating the right conditions for people to confront their distress, so they can generate new solutions for resolving their problems, is what separates psychedelic drugs from the way in which we use other medications, which may only provide short-term relief. Expecting psychedelic drugs to do all the work on their own, however, is not helpful for the advancement of mental healthcare; it is the talking therapy which targets psychological reorganisation that must be focused on.

Mental health difficulties are not caused by biochemical imbalances in the brain. Our mental health is multifaceted and influenced by numerous factors, such as chronic stress, historic trauma, levels of social support, and the meaning we make of it all. Working with mental health issues, therefore, is not just about creating changes to receptors in the brain; it is about having a multifaceted approach to dealing with the very idiosyncratic issues that lead to people becoming distressed.

A drug-centred, dose-response approach in psychedelic research may, misleadingly, communicate that mental health issues are simply the result of some deficit that needs to be rectified and the drug alone is the vehicle of change.

Losing focus on the role of therapy risks overplaying the importance of neurological mechanisms that contribute to mental health, whilst underplaying social, cognitive, emotional, and behavioural processes underlying mental distress.

It might be dangerous to regard psychedelic drugs as silver bullets that can directly solve mental health problems. This is a reductionistic understanding of the problems that affect peoples mental health and one that could give false hope to those who seek help. Early-stage clinical research indicates that psychedelics could be an important component of what must be a multifaceted approach, where emphasis on psychological processes is, at least, as important as what is happening biologically.

Psychedelic drugs may help people experience their problems in ways that they havent been able to before, leading to novel insights which potentially allows new solutions to be generated. In this respect, the drug is more of a catalyst that can enable people to develop awareness of the root causes of their difficulties. To quote the director of the Multidisciplinary Association for Psychedelic Studies (MAPS), Rick Doblin in the New York Times, Its not the drug its the therapy enhanced by the drug.

Psychological support provided during psychedelic-assisted therapies, whether it is non-specific support or shaped by a therapeutic model, is designed in three phases: preparation, dosing, and integration. In preparation, the therapist builds a therapeutic alliance with the participant and prepares them for what to expect. The drug is administered in the dosing session in which the therapist(s) supports the participant for the duration of the drugs effects. The integration phase focuses on making sense of the experiences the participant had during dosing and on helping them incorporate the insights and lessons learned into their daily lives.

It is widely posited that the integration phase plays an important part in generating insights from psychedelic experiences and facilitating the chance of meaningful long-term change. Yet, clinical research into what the specific mechanisms of change are and the most efficacious methods for facilitating such change is limited. A clear, empirically sound framework of understanding is needed, which provides a coherent understanding of individuals mental distress and informs a clear set of principles on which interventions can be based.

People who seek treatment from mental health services often experience multiple and varied issues, yet current practice usually involves providing a problem specific intervention based on a diagnosis. For example, there are hundreds of problem-specific talking therapies, which can be confusing for service users and unduly expensive when training mental health service providers in hundreds of approaches. We therefore need approaches that place the individual at the centre and can deal with the varied problems they face from their perspective.

Our upcoming trial, a collaboration between the University of Manchester and Clerkenwell Health, aims to investigate the impact of talking therapy alongside two different doses of psilocybin. The therapy is informed by Perceptual Control Theory (PCT), which understands mental health issues as the result of a person having reduced or loss of control over the things they value in life, usually because there are two or more competing goals that are mutually incompatible.

PCT provides an empirical framework of understanding that helps to integrate findings from across the mental health literature and informs clinical practice by identifying and capitalising on key principles common to many effective psychotherapeutic interventions. This framework advocates helping people develop their own solutions to problems by mobilising their attention to different aspects of their experiences in order to evaluate them from different perspectives.

There is an emphasis on helping people develop awareness of important values and goals so that they can work out new ways to balancing competing needs. In this respect, psilocybin may serve a useful role in helping an individual redirect their awareness to what is most salient for them, as opposed to other more directive therapeutic approaches.

A number of other therapeutic approaches are emerging for psychedelics, including the Psychedelic Harm Reduction and Integration framework used by MAPS, which has yielded promising results in early research trials. Research in this field is still in its infancy, yet what is becoming increasingly clear, is that service users must be at the centre of psychedelic-assisted therapy and the therapists role should be to guide rather than instruct.

In the Clerkenwell Health trial, psilocybin is understood as temporarily reducing our use of strategies to control experiences, including those that may be counterproductive like worry and rumination. This enables us to be exposed to emotions and wider experiences that we might not have been able to identify or focus on before.

In conclusion, we cannot expect the drug to do all the work on its own. We need more focus on the therapy, which creates the conditions required for people to get themselves better. If we want to improve clinical practice for those who seek help, a principles-based, theoretically driven approach, which builds on what is known to be useful across different psychotherapies is essential. This needs more clinical research. Developing best practices through clinical research, and more importantly, sharing these practices, is crucial for psychedelic-assisted therapy to be incorporated into mainstream clinical practice.

Visit link:

Are psychedelics the whole answer? | MHT - Mental Health Today

Psychedelic Therapy: Uses, How It’s Done, Risks, and More – Healthline

Psychedelic therapy (sometimes referred to as psychedelic-assisted psychotherapy, or PAP) is a type of psychiatric practice that involves ingesting a psychedelic substance as part of a psychotherapeutic process.

In psychedelic therapy, the use of psychedelics is typically combined with talk therapy.

A range of consciousness-altering psychedelic drugs are currently being used or researched for therapeutic purposes in both clinical and nonclinical settings.

Some are derived from plants, like psilocybin (magic mushrooms), DMT, peyote, ayahuasca, and ibogaine. Others including ketamine, MDMA, and LSD are chemical compounds.

While Indigenous communities have used psychedelics in therapeutic and religious settings for centuries, psychedelic therapy is relatively new in Western clinical settings.

Its becoming more popular with increased legalization of certain psychedelic substances, a rise in mental health conditions, and a lull in psychopharmacological research.

Between the 1950s and 1970s before former President Richard Nixon outlawed them with the Controlled Substances Act scientists produced a breadth of evidence both verifying and pointing toward the therapeutic potential of psychedelic therapy to treat:

In recent years, renewed interest and investment have fueled additional research, much of which is ongoing.

Heres a look at the potential uses of various psychedelics.

Ketamine is the most-studied psychedelic drug for mental health therapy.

In low doses, it has shown to be beneficial in numerous trials exploring its potential to treat depression, but its effects are short-lived.

For people with severe depression, for example, research shows significant improvement after treatment, and results last about 6 to 8 weeks, on average.

These findings have led to the development of a drug called Spravato. Its a nasal spray that delivers the active ketamine ingredient. However, intravenous ketamine administration is considered to be more effective and less expensive.

Multiple phase 2 clinical trials which are done to discern whether a treatment works suggest that MDMA can treat PTSD symptoms for up to 4 years.

Researchers have also completed a phase 3 trial, which determines whether a treatment works better than whats currently available, involving MDMA-assisted therapy for PTSD. This was the first phase 3 trial of any psychedelic-assisted therapy.

Among 90 participants with severe PTSD, 67 percent no longer qualified for a PTSD diagnosis after three treatments, and 88 percent had reduced symptoms of PTSD.

The trial sponsor, the Multidisciplinary Association for Psychedelic Studies, says the results could make way for Food and Drug Administration (FDA) approval by 2023.

Psilocybin, the main compound in magic mushrooms, has shown positive results in treating depression and anxiety in people living with terminal illnesses.

Experts believe it could also help with obsessive-compulsive disorder, addiction, and treatment-resistant depression, but more research is needed.

LSD, a long lasting, potent psychedelic thats considered to be the prototype for therapeutic psychedelics, has been shown to help with both alcohol use disorder and anxiety in people living with terminal illnesses.

At this stage, clinicians are still evaluating the effectiveness of their treatments, so exact dosing, number of treatments needed, and the approach to psychedelic therapy will vary depending on who is guiding you.

That said, most psychedelic therapy in clinical settings is conducted via three stages:

The first step is usually a preparatory consultation to ensure that you dont have any contraindications to the treatment. This is also a good opportunity to discuss your personal background and any goals or concerns you have around psychedelic therapy.

The second phase involves ingesting, either orally or via injection, the psychedelic substance under the supervision of a trained therapist.

There are usually multiple sessions, depending on the type of psychedelic and the treatment plan. For example:

The final phase is the integration process, when the therapist and client work together to integrate meaning from the psychedelic experiences.

Some experts have expressed concerns at the rise of self-medicating, particularly after the 2020 Global Drug Survey showed an increase in the number of people who say they are self-treating various mental health concerns with psychedelics.

Many of these concerns stem from the potential contamination of substances that dont come for a lab-tested source, along with the lack of medical supervision.

Otherwise, psychedelic substances are generally considered low risk, especially when used in a clinical setting.

MDMA can sometimes cause short-term high blood pressure, increased heart rate, and elevated body temperature, but these effects typically go away after use.

Psilocybin may similarly elevate blood pressure temporarily or cause light headaches.

That said, psychedelics have been linked to an increased risk of psychosis in people with psychotic disorders or a predisposition to them.

Theres also the risk, particularly with LSD use, of hallucinogen persisting perception disorder (HPPD). This is a rare condition involving intense flashbacks and hallucinations. However, experts note that this appears to be more common when using substances without medical supervision.

There are a few concerns about ibogaine, including a possible link to potentially fatal cardiac arrhythmias. As a result, its been limited to observational trials so far with a focus on treating opioid addiction.

Theres a lot of excitement around the potential of psychedelic therapies. As a result, a lot of new therapists, gurus, international retreats, and clinics are opening up.

If youre interested in participating in a psychedelic-assisted treatment in a clinical setting supported by an expert, a good place to start is the database of accredited therapists maintained by the Multidisciplinary Association for Psychedelic Studies.

The association also welcomes questions or concerns about psychedelic-assisted therapy, and can make recommendations to help guide you.

Whether its a clinical setting or a retreat, its important to understand that ingesting psychedelic substances alters consciousness and can make you vulnerable to suggestion.

As a result, some participants in studies or treatments have alleged unethical and sometimes even criminal behavior. Read reviews, evaluate accreditation, and consider how you might ensure accountability should anything go awry during or after treatment.

Theres still a lot to learn about the potential of psychedelic therapy, but the existing research is promising, particularly for those with severe PTSD.

Because of this, advocates and lobbyists are working to decriminalize some psychedelic substances to improve access and research opportunities. Stay tuned, because these treatment options are evolving each week.

Kate Robertson is a Toronto-based editor and writer who has focused on drugs, primarily cannabis, since 2017. She has been published in The Guardian, Macleans magazine, the Globe and Mail, Leafly, and more. Find her at @katierowboat.


Psychedelic Therapy: Uses, How It's Done, Risks, and More - Healthline